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ABSTRACT
TARGETING THE ENDOCANNABINOID SYSTEM TO REDUCE NOCICEPTION
By Lamont Booker, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011
Major Director: Dr. Aron Lichtman, Professor, Department of Pharmacology & Toxicology

Pain of various etiologies (e.g., visceral, inflammatory) can be a debilitating disorder that
presents a problem of clinical relevance. While it is known that ∆9-tetrahydrocannabinol (THC)
the primary psychoactive constituent found in marijuana produces analgesia in various rodent
models of pain, its pharmacological properties are overshadowed by its psychomimetic effects.
THC is the primary phytocannabinoid found in marijuana though other prevalent constituents
such as the phytocannabinoids (e.g., cannabidiol (CBD), cannabinol (CBN), cannabichromene
(CBC), tetrahydrocannabivarin (THCV)) may possess antinociceptive actions without the
psychomimetic effects associated with THC. Indeed, these phytocannabinoids act upon the
endocannabinoid system (ECS) that is comprised of the CB1 and CB2 cannabinoid receptors,
endogenous ligands (anandamide (AEA), 2-arachidonoyolglycerol (2-AG)), and
endocannabinoid biosynthetic and catabolic enzymes. We hypothesize that phytocannabinoids
as well as endocannabinoid catabolic enzyme inhibitors reduce nociception preclinical models of
pain. In the first series of studies, the antinociceptive effects of prevalent phytocannabinoids

were evaluated in the acetic acid stretching test, a rodent visceral pain model. While CBN and
THC both produced antinociceptive effects via a CB1 mechanism of action, CBC, and CBD had
no effect on nociception. Conversely, THCV antagonized the antinociceptive effects of THC.
These results suggest that various constituents of marijuana may interact in a complex manner to
modulate pain.
Since the THC and CBN displayed their effects via specific endogenous cannabinoid
receptors, we investigated whether increasing endocannabinoids block nociceptive behavior.
Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and
elicits antinociceptive effects, without psychomimetic issues associated with THC. Similarly,
blockade of another endocannabinoid catabolic enzyme monoacylglycerol lipase (MAGL)
elevates (2-AG) and elicits antinociceptive effects. Therefore, we tested the hypothesis that
FAAH and/or MAGL inhibition blocks nociception in the acetic acid abdominal stretching
model, and the LPS-induced allodynia (i.e. painful response to a non-noxious stimuli) model of
inflammation.
Genetic deletion or pharmacological blockade of FAAH or pharmacological blockade of
MAGL significantly reduced the total number of abdominal stretches in the visceral pain model.
Additionally, blockade of both enzymes simultaneously produced an enhanced antinociceptive
effect versus blocking the enzymes individually. These effects were mediated through CB1
receptors. However, in the LPS-induced allodynia model, FAAH inhibited anti-allodynic effects
through a CB1 and CB2 receptor mechanismn. In both assays other potential targets of FAA

substrates (i.e., mu-opioid, TRPV1, and PPAR-alpha receptors) did not play an apparent role in
FAAH inhibited antinociceptive responses. Taken together, these results illustrate that targeting
the endocannabinoid system via direct acting agonists such as the phytocannabinoids, or indirect
methods (i.e. inhibiting degradative enzymes of the endogenous cannabinoids), represents a
promising strategy to treat pain.

Chapter 1. Introduction

Pain (e.g. visceral, inflammatory) can be a debilitating disorder that greatly affects the
quality of life. It accounts for one of the top reasons for emergency department visits according
to the National Health Statistics Report (CDC, 2008). In addition, analgesic compounds tend to
be the leading type of therapeutic agents mentioned during these visits. While these analgesic
compounds range in degree of effectiveness, they present greater issues when taken chronically.
For example, repeated opioid use can lead to tolerance, opiate-induced hyperalgesia,
constipation, and the potential of addiction (Mitra, 2008; Ossipov et al., 2003). Another example
is the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs). Chronic use of these
drugs can cause gastric ulcers (Chan and Leung, 2002), and ultimately potentiate visceral pain.
As a part of this dissertation, we investigate alternative targets for alleviating visceral and
inflammatory pain. More specifically, we explore the effects of plant-derived cannabinoids as
well as the endogenous cannabinoid system (ECS) and their impact on modulating nociceptive
behavior. To date, marinol, which is synthetic THC, and cesamet a synthetic cannabinoid are the
only FDA-approved class of cannabinoids and can be used to treat nausea and emesis elicited by
cancer chemotherapy and as an appetite stimulant in patients suffering from AIDS-related
cachaxia.
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Cannabis sativa
Marijuana has been used and cultivated for a variety of purposes as archaeological
evidence dates back to the 2350 B.C (cannabinoids in nature and medicine 2009). Such
examples are the use of cannabis for its cooking oil from cultivated seeds, fiber for making rope
and paper, and medicinally (headaches, parasites, antibiotic, analgesic, hypnotic) (Russo, 2007).
In 1937, the US Congress implemented and adopted the Marijuana Tax Act. The tax act posed a
tax on buyers, sellers, importers, growers, physicians, veterinarians, and any other persons who
deal in marijuana commercially, prescribe it professionally, or possess it. Ultimately the tax act
eliminated further medicinal use and nearly halted all research in the field for several years.
Although marijuana was illustrated to have medicinal value, its psychoactive properties
sparked an exponential increase in its recreational use. According to a recent 2009 survey,
marijuana is the most commonly used and abused illicit drug in the United States of America
with an estimated 16.7 million people reporting past-month use (NIDA- SAMHSA, 2010).
Today marijuana is defined as a schedule I controlled substance considered not to be legitimate
for medicinal use. Cannabis sativa is comprised of 489 identified constituents of various
terpenoids, cannabinoids, flavonoids, amino acids, carbohydrates, fatty acids, and hydrocarbons
(Elsohly and Slade, 2005). Delta-9-Tetrahydrocannabinol (THC) is the most prevalent and well
characterized constituent of the approximately 70 cannabinoids identified in cannabis (Elsohly
and Slade, 2005), and largely accounts for the psychoactive properties of this plant. Other
2

prevalent phytocannabinoids that are structurally similar to THC include cannabinol (CBN),
cannabidiol (CBD), cannabichromene (CBC), and tetrahydrocannabivarin (THCV) (see Table 1).
Each of these compounds has been found to possess pharmacological properties of their own.
The extent to which these phytocannabinoids and other constituents found in marijuana interact
with each other, may contribute to marijuana's overall pharmacological effects.
In 1899 the first attempt was made to identify a cannabis constituent which was
discovered to be that of CBN from the resin of Indian hemp (Wood et al., 1899). Almost half a
century later other cannabinoid constituents were isolated and identified. Cannabidiol (CBD)
was the second phytocannabinoid isolated (Adams et al., 1940) however its structure
identification would come years later (Mechoulam & Shvo, 1963). CBD was tested in volunteer
studies and reported as not being the active ingredient resulting in the narcotic activity reported
with the use of marijuana. In 1964, the main psychoactive ingredient found in marijuana,
tetrahydrocannabinol (THC) was isolated from hashish by column chromatography and its
structure was determined by correlations with known terpenoids (Gaoni & Mechoulam, 1964).
The development of the mass spectrometry, infrared spectroscopy, and nuclear magnetic
resonance allowed for ease in the future identification of other prevalent phytocannabinoids
found in marijuana. Cannabichromene (CBC) was identified as a new active principle in hashish
in 1966 (Gaoni & Mechoulam, 1966) followed by cannabivarin (CBV) and
tetrahydrocannabivarin (THCV) in 1971(Merkus, 1971). Soon after the elucidation of the
structure of THC there was a growing interest in the production of synthetic THC analogs. To
3

date, there are numerous synthetic cannabinoids that have been synthesized that share
pharmacological properties similar to THC, although more potent. An example of a synthetic
cannabinoid is CP-55,940 synthesized by Pfizer (Koe et al., 1985). CP-55,940 along with
several other synthetic compounds such as HU-210 (Howlett et al., 1990), and WIN55-212
(D'Ambra et al., 1992) were synthesized soon after which helped advance the study about
cannabinoids and their pain-relieving effects. These synthetic cannabinoids as well as THC
show different binding affinities for the CB1 and CB2 receptors which results in differences in
potency. Additionally, unlike THC which is a partial efficacy agonist in vitro, synthetic
cannabinoids produced full agonist like properties (Matsuda et al., 1990). The range of
published affinities (nM) in reverse order of potency of these compounds for the CB1 receptor
are THC (35.3-80.3), WIN 55,212-2 (1.89-123), CP-55,940 (0.5-5.16), HU-210 (0.061-0.82),
and CB2 receptor are THC (3.9-75.3), CP-55,940 (0.69-19.8), WIN 55,212-2 (0.28-16.2), HU210 (0.17-0.52) (Howlett et al., 2002; Ibrahim et al., 2003) (see Table 2). Due to the fact that
these new synthetic compounds were very potent, and assuming they bound to a specific
receptor, they were used as labeled ligands. In 1988 tritium-labeled CP-55,940 was used to
identify specific binding sites in the brain for cannabinoids, which provided evidence and
prompted a search for an endogenous receptor system (Devane et al., 1988). The selective
binding of this compound helped in identifying the cannabinoid receptors and the
evolution/expansion of knowledge of the endocannabinoid system.

4

Table 1. Discovery and isolation of prevalent cannabinoid constituents found in marijuana.

Phytocannabinoids

Structure

Year Isolated
1964

Tetrahydrocannabinol
(THC)
(Gaoni & Mechoulam, 1964)

1971
Tetrahydrocannabivarin
(THCV)
(Merkus, 1971)

1966
Cannabichromene
(CBC)
(Gaoni & Mechoulam, 1966)

1940
Cannabidiol
(CBD)
(Adams et al., 1940)

1899
Cannabinol
(CBN)
(Wood et al., 1899)
5

Table 2. Synthetic cannabinoids and their relative potencies at the CB1 receptor. The potency
range is depicted as the concentration of unlabeled drug which displaced tritiated compounds
from CB1 receptor see references for review (Howlett et al., 2002; Pertwee et al., 2010).

Synthetic Cannabinoids

Structure

Potency at CB1 receptor

CP-55,940

0.5-5.0 nM

HU-210

0.06-0.73 nM

WIN55-212

1.89-123

6

Table 3. Endocannabinoid catabolic enzyme inhibitors.

Inhibitor

Structure

Target
Irreversible FAAH
(Boger et al., 2005,

URB597

Piomelli et al., 2006)
Reversible FAAH
OL-135

(Boger et al., 2005)

Irreversible FAAH
PF-3845

(Ahn et al., 2009)
MAGL
(Labar et al., 2010)

JZL184

MAGL
N-arachidonylmaleimide

(Labar et al., 2010)

MAGL and FAAH
URB602

(Labar et al., 2010)

7

Endocannabinoid system
The endocannabinoid system consists of G-protein coupled receptors which are
associated with Gi/o G-proteins (for review see (Howlett et al., 2002). Activation of these
receptors decreases cAMP production via blockade of adenylyl cyclase (Howlett et al., 1990),
activation of inwardly rectifying potassium (GIRK) channels via Gβγ subunits (Mackie et al.,
1995; McAllister et al., 1999). Furthermore activation of the cannabinoid receptor inhibits Nand P/Q-type calcium channels, which reduces synaptic vesicle fusion to the nerve terminal
thereby inhibiting the release of excitatory and inhibitory neurotransmitters. The consequence of
this effect leads to a decrease in post-synaptic depolarization. To date, two primary cannabinoid
receptors have been cloned. The first receptor is the cannabinoid receptor type 1 (CB1) and is
located heterogeneously throughout the central nervous system (CNS) (Matsuda et al., 1990;
Munro et al., 1993; Zimmer et al., 1999), and is believed to mediate marijuana’s psychomimetic
effects. In support of this notion, cannabinoids induce tetrad effects (decrease in locomotor
activity, hypothermia, catalepsy, and analgesia) are reversed with a CB1 antagonist and in CB1
(-/-) mice (Compton et al., 1996; Rinaldi-Carmona et al., 1994). The cannabinoid receptor type 2
(CB2) was identified in a human promyelocytic leukaemia cell line soon after the CB1 receptor
was discovered (Munro et al., 1993). CB2 receptors are expressed predominately in cells of the
immune and hematopoietic systems (Cabral and Marciano-Cabral, 2005), though CB2 receptor
messenger RNA and protein are expressed in microglia (Carlisle et al., 2002; Nunez et al., 2004)
and brainstem neurons (Onaivi et al., 2006; Van Sickle et al., 2005). Activation of CB2
8

receptors also modulates cytokine secretion (Klein et al., 2003), reduces proliferation (Lombard
et al., 2007), and suppresses monocyte chemotaxis through PI3K/Akt and ERK1/2 signaling
(Montecucco et al., 2008). CB1 and CB2 receptors share approximately 44% homology with
each other (Munro et al., 1993). CB1 receptors are located primarily in neuronal tissue and
therefore may play a major role in analgesia. Conversely, CB2 receptors are located primarily
on immune cells and may be more involved in reducing inflammatory mediated effects. The
distribution of both cannabinoid receptors provides an anatomical basis for the analgesic effects
of cannabinoids. Cannabinoid receptors have been localized on presynaptic terminals of both
GABAergic (Katona et al., 1999) and glutamatergic neurons (Huang et al., 2001; Szabo and
Schlicker, 2005). Transient suppression of the inhibitory transmission (i.e. GABA) is termed
depolarization-induced suppression of inhibition (DSI). Conversely transient suppression of the
stimulatory neurotransmitter (e.g. glutamate) is called depolarized-induced suppression of
excitation (DSE). Both result in cannabinoid receptor hyperpolarization of a repetitively
depolarized neuron, which suppresses subsequent vesicular fusion and release of glutamate or
GABA. This is the case with activation of cannabinoid receptors found on glutamatergic
neurons (Maejima et al., 2001).
Endogenous ligands which bind to and activate the cannabinoid receptors were
discovered and termed endocannabinoids (eCBs) (Di Marzo and Fontana, 1995)). These
endocannabinoids are derived from phospholipid precursors in the postsynaptic neuron. Unlike
classical neurotransmitters or neuromodulators, endocannabinoids are not stored in vesicles, but
9

are released on demand and travel in a retrograde manner from post-synaptic terminals to the
pre-synaptic terminals to act on cannabinoid receptors. The first endocannabinoid isolated from
the brain was anandamide (AEA) (Devane et al., 1992), followed by 2-arachidonoylglycerol (2AG) (Mechoulam et al., 1995; Sugiura et al., 1995). Additionally, three other endocannabinoids
have been discovered which are derivatives of arachidonic acid. These putative
endocannabinoids which have non selective activity are noladin ether (Hanus et al., 2001),
virodhamine (Porter et al., 2002), and N-arachidonoyldopamine (NADA) (Huang et al., 2002).
However, the most studied and well characterized ligands are AEA and 2-AG.
Different enzymes are responsible for the synthesis of AEA and 2-AG. AEA synthesis is
regulated by multiple pathways, but the most widely accepted pathway is via the cleavage of Narachidonoyl-phosphatidylethanolamine (NAPE). NAPE is then hydrolyzed by NAPEphospholipase D forming AEA. However, a previous study (Leung et al., 2006) showed that
NAPE-PLD knockout mice still possess wild-type levels of AEA. Alternatively at least two
other hypotheses arose such as AEA synthesis via phosphodiesterase (PDE), or synthesis via
cleavage of phospholipase C (PLC) and a phosphatase (Liu et al., 2006). On the other hand, 2AG is synthesized by the cleavage of diacylglycerol (DAG) by DAG lipase-alpha (DAGLα)
(Gao et al., 2010; Tanimura et al., 2010). In these previous studies they demonstrated that
DAGLα knockout mice when compared to DAGLβ knockout mice showed a significantly
lesser production of 2-AG levels.

10

As with most signaling messengers, AEA and 2-AG are rapidly inactivated soon after
they are released. AEA is taken back into the post-synaptic terminal and degraded by the
enzyme fatty acid

Figure 1. Overview of the Endocannabinoid Signaling System

amide hydrolase
(FAAH) (Cravatt et
al., 1996)(Giang
and Cravatt, 1997).
FAAH is located
within the postsynaptic terminal
and is responsible
for the degradation
of other amides
such as oleamide,
the sleep agent, palmitoylethanolamide (PEA), the anti-inflammatory agent, and
oleoylethanolamide (OEA) the satiety lipid (Cravatt et al., 1995). Conversely, approximately
85% of 2-AG is degraded within the presynaptic terminal by the enzyme monoacylglycerol
lipase (MAGL). The remaining 2-AG is degraded by enzymes alpha/beta hydrolase 6 and 12
(ABHD) (Blankman et al., 2007). Although 2-AG is present at levels 170-1000 (Stella et al.,
1997; Sugiura et al., 2002) fold greater than AEA, both endocannabinoids produce some
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cannabinoid effects as evaluated by the classical “Tetrad”. This battery of four tests, is used to
assess for cannabimimetic activity, and includes: spontaneous locomotor suppression, analgesia
to noxious thermal stimuli, catalepsy, and hypothermia (Compton et al., 1993; Martin et al.,
1991b). Externally administered THC or other synthetic cannabinoids do not mimic the
physiological effects of locally released on demand endocannabinoids because their overall
effect is to cause a persistent inhibition of neurotransmitter release, and not the localized and
transient effects seen with endocannabinoids (Vaughan and Christie, 2005). Thus exploitation of
the endocannabinoid system may have a more applicable implication in the clinical setting.
Several genetic and pharmacological tools have been developed to help better understand
the role of the endocannabinoid system such as FAAH knockout mice, FAAH neuronal specific
knock-in mice, selective pharmacological agents against FAAH, and pharmacological agents
selective for inhibiting MAGL. FAAH (-/-) mice display 15 fold elevated AEA levels in the
brain and show an antinociceptive phenotype ((Cravatt et al., 2001; Lichtman et al., 2004)). In
addition to genetic blockade of FAAH, pharmacological effects have also been demonstrated.
Irreversible (PF-3845, URB597) and reversible (OL-135) inhibitors of FAAH (see Table 3) have
been demonstrated to elevate AEA levels in the brain ((Ahn et al., 2009; Boger et al., 2005;
Fegley et al., 2005)) and produce analgesia in a variety of animal models of pain (see review
(Schlosburg et al., 2009b)). Additionally, complementary approaches to investigate CB1 and
CB2 receptor involvement includes genetically modified mice lacking either the CB1 or CB2
receptor. In addition, selective CB1 (rimonabant, AM251) and CB2 receptor antagonists
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(SR144528, AM630) have also been generated. These complementary genetic and
pharmacological approaches are used in this dissertation to determine cannabinoid receptor
mechanism of action.
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Rationale and Hypothesis

The overall goals for this dissertation were to investigate the effect of prevalent
phytocannabinoids in commonly used mouse models of pain, and determine whether elevating
endocannabinoids by blocking their hydrolysis is a viable approach to treat pain. We
hypothesize that direct activation of the endocannabinoid system by phytocannabinoids or
indirectly activating the endocannabinoid system by blocking hydrolyzing enzymes reduce pain.

Phytocannabinoids and abdominal stretching
Although THC has been well established to produce antinociceptive effects in the several
models of nociception such as the tail-flick (Martin et al., 1984), inflammatory pain (Smith et al.,
1998), and neuropathic pain (De Vry et al., 2004), other prevalent phytocannabinoids that are
structurally similar to THC have not been assessed. These compounds include CBN, CBD,
CBC, and THCV. CBD has been demonstrated to have anti-edema effects (Costa et al., 2004;
Lodzki et al., 2003) and potentiate the antinociceptive effects of THC (Hayakawa et al., 2008;
Varvel et al., 2006). However, orally administered CBD was inactive in the acetic acid
stretching model and CBN was only effective at high concentrations (Sanders et al., 1979; Sofia
et al., 1975; Welburn et al., 1976). In addition, neither CBC nor THCV has been characterized
in visceral pain models.
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Interestingly, THCV has been shown to act as a competitive cannabinoid receptor agonist and
antagonist (Pertwee, 2008; Thomas et al., 2005). We hypothesize that prevalent
phytocannabinoids that are structurally similar to THC produce analgesia via a cannabinoid
receptor mechanism of action. To test this hypothesis, we compared the antinociceptive effects
of THC to other prevalent phytocannabinoids, including CBC, CBD, CBN, and THCV, in the
acetic acid stretching model. Furthermore, we tested the ability of THCV to antagonize the
effects of THC in our model since it was shown previously to act as an antagonist in vitro
(Thomas et al., 2005). Previously, it was discovered that CBD did not show affinity for the CB1
receptor and CBN was reported to have moderate to low affinity for the CB1 receptor (Devane et
al., 1988). THCV and CBC binding affinities have not been reported to date. Therefore, we
assessed the binding affinities of prevalent marijuana constituents. A secondary goal of this
chapter is to determine whether phytocannabinoids produce their antinociceptive effects through
a specific cannabinoid receptor mechanism of action. Accordingly, we examined the
involvement of CB1 and CB2 receptors using rimonabant and SR144528, selective antagonists
for these respective receptors. Because cannabinoids elicit antinociceptive effects as well as
motor suppressive effects, in the final set of experiments, we evaluated each active drug for
hypomotility.
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Endocannabiniod degradative enzyme inhibitors and abdominal stretching
To test the idea that the endogenous cannabinoid system may represent a target for
treating visceral pain we employed the acetic acid abdominal stretching model. The acetic acid
stretching model offers great benefits in that in can rapidly depict compounds that have analgesic
properties. A second major goal of this project was to determine whether elevating
endocannabinoids, anandamide or 2-arachidonoylglycerol by blocking their hydrolysis attenuates
visceral pain. Initially, we examined the role of the endocannabinoid system and the possible
mechanisms through which it can reduce abdominal stretching. Previous studies have shown
that blocking FAAH produces antinociception without producing cannabimimetic effects such as
hypothermia, catalepsy, and hypomotility (Cravatt et al., 2001; Gobbi et al., 2005; Kathuria et
al., 2003; Lichtman et al., 2004). Additionally, no study to date has assessed the effects of
MAGL inhibition on abdominal stretching. Hence, we hypothesize that inhibiting FAAH and or
MAGL produces antinociceptive effects similar to that of the phytocannabinoid, THC, through a
CB1 mediated mechanism of action in the acetic acid abdominal stretching model. To test the
effects of FAAH inhibition, we examined whether FAAH (-/-) mice or FAAH wild-type mice
treated with FAAH inhibitors (URB597, OL-135, PF-3845) would display reduced nociceptive
behavior in the acetic acid induced abdominal stretching test. Second, we determined the
receptor mechanism of action underlying the antinociceptive phenotype of FAAH-knockout
mice. In order to determine the receptor mechanism of action, mice were evaluated with the
respective CB1 and CB2 receptor antagonists, rimonabant and SR144528. Because the
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antinociceptive effects of FAAH inhibitors have been suggested to include an opioid receptor
mechanism of action (Chang et al., 2006), we also evaluated whether naltrexone would block the
antinociceptive effects of URB597 and OL-135.
Previous studies illustrated that coadministration of an NSAID and a synthetic
cannabinoid agonist, WIN55-212 elicited additive analgesic effects in the acetic acid abdominal
stretching model (Ulugol et al., 2006). However, WIN55-212 produces THC-like
cannabimimetic properties such as hypomotility, catalepsy, and hypothermia. Conversely,
FAAH inhibition does not produce these side effects, therefore we tested the hypothesis that dual
FAAH and COX inhibition reduce acetic acid abdominal stretching. Furthermore, since FAAH
and COX regulate different signaling pathways we conducted isobolographic analysis to
determine if there is a synergistic interaction by blocking both enzymes.
To test the hypothesis that blockade of MAGL, another degradative enzyme in the
endocannabinoid system, produces antinociception in an acute model of visceral pain, we
employed the use of the selective MAGL inhibitor JZL184 (Long et al., 2009). Furthermore, we
determined if the observable antinociceptive effects of MAGL inhibition are mediated through
CB1 receptors. Given the fact that FAAH and MAGL are localized in different regions of the
neuron (e.g., FAAH postsynaptically located, MAGL presynaptically), and regulate different
endocannabinoids, the possibility exists that they may have different roles in regulating
physiological functions including nociception. Thus, simultaneous inhibition of FAAH and
MAGL might offer an attractive therapeutic approach that maintains analgesic efficacy while
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minimizing untoward side effects associated with direct acting cannabinoid agonists. For that
reason, we determined if dual inhibition of FAAH and MAGL would enhance the
antinocicpetive effects in the acetic acid abdominal stretching model compared to inhibiting one
enzyme.

FAAH and LPS-induced allodynia
Another preclinical model of pain is the LPS-induced allodynia model. Unlike the acetic
acid model of visceral nociception which affects the internal organs of the viscera, the LPS
model of allodynia models clinical diseases such as fibromyalgia, postherpetic neuralgia and
various skin disorders. In the final series of experiments, we examined the role of FAAH and
MAGL inhibition on reversing allodynia. Lipopolysaccharide (LPS) is a bacterial endotoxin
derived from the outer cell wall of gram (-) bacteria. When LPS is injected into the plantar
surface of the mouse paw, it elicits a mild innate or non-specific inflammatory response. The
innate response is characterized by an infiltration of immune cells, the release of cytokines and
chemokines, and activation of complement cascades to remove the bacteria. The resulting
response is the induction of tactile allodynia (painful response to a non-noxious stimuli) as seen
in patients with fibromyalgia, post herpetic neuralgia, and mild skin injuries (Rowbotham and
Fields, 1989; Staud and Domingo, 2001). Hence, we tested the hypothesis that genetic deletion
or pharmacological inhibition of the endocannabinoid catabolic enzyme FAAH, blocks tactile
allodynia associated with inflammation.
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Although an LPS model of inflammatory pain was recently characterized, administration
of these high concentrations of LPS resulted in overt paw edema, weight loss, and malaise in
mice (Naidu et al., 2010). Therefore our first aim was to modify the previously characterized
LPS model of inflammation to induce tactile allodynia without producing overt edema of the
paw or eliciting a general malaise. To ensure that our model can detect compounds that produce
analgesia, we tested the GABA analog gabapentin, which possesses efficacy in treating various
types of pain (Staahl et al., 2009) and serve as our positive control. In addition, we examined the
effects of global activation of cannabinoid receptors, using THC. Since FAAH (-/-) mice show
elevated levels of anandamide and hypoalgesia in acute models of pain (Lichtman et al., 2004)
we determined if genetic deletion of FAAH reduces LPS-induced allodynia. FAAH-NS mice
were previously generated to distinguish the function of endogenous fatty acid amides in the
nervous system and peripheral tissues (Cravatt et al., 2004). These mice were developed by our
collaborators by excising FAAH cDNA from the pcDNA3 vector and subcloned into the pNSEEx4 vector by blunt end cloning for expression under the neural-specific enolase promoter. This
construct was injected into embryos and transgenic FAAH-NS offsprings were identified. The
transgenic mice were intercrossed with FAAH (+/-) mice and FAAH (-/-) mice and backcrossed
onto the C57BL/6 strain. With the use of southern blot analysis, it was determined that FAAHNS mice expressed FAAH in the nervous system (brain and spinal cord) and not peripheral
tissues (e.g. liver, spleen, kidney, testis, neutrophils) (Cravatt et al., 2004). We used FAAH-NS
mice to distinguish whether inhibiting FAAH expressed in the peripheral and/or nervous
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system(s) mediates the observed anti-allodynic effects. In a similar manner, we examined
whether pharmacological blockade of FAAH would reverse LPS-induced allodynia by
comparing the anti-allodynic effects of the reversible FAAH inhibitor OL-135, two irreversible
FAAH inhibitors, URB597, and PF-3845. In addition, we used LC/MS/MS analysis to quantify
endocannabinoid levels and compare them to mice treated with vehicle after systemic or local
administration of PF-3845. Several studies have implicated a role for CB1 receptors in reducing
hyperalgesia and CB2 receptors in ameliorating edema (see review (Anand et al., 2009)). Thus,
we sought to determine whether these two cannabinoid receptors play a role in the anti-allodynic
effects of FAAH (-/-) mice or wild type mice treated with FAAH inhibitors. Due to the fact that
FAAH regulates other fatty acid amides other than anandamide, and since anandamide has
affinities for other receptors besides cannabinoid receptors, we examined the effect of inhibiting
various non-cannabinoid receptors. These receptors include the µ-opioid receptor, which was
previously shown to mediate the anti-hyperalgesic response in the rat spinal nerve ligation and
mild thermal injury models (Chang et al., 2006), the TRPV1 receptor, which was reported to
play a vital role in the antinociceptive effects of AEA in the thermal hyperalgesia model of
inflammation (Horvath et al., 2008), and the PPAR-α receptor, which was shown to mediate the
antihyperalgesic effects of URB597 in an acute model of inflammation (Jhaveri et al., 2008).

20

Chapter 2: General Methods
Subjects
The subjects consisted of male ICR mice (Harlan Laboratories, Indianapolis, Indiana), adult
male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME), adult male and female FAAH (-/-)
mice backcrossed for at least 13 generations onto a C57BL/6J background, and male and female
FAAH (+/+) mice derived from the same line of FAAH (+/-) breeders used to derive FAAH (-/-)
mice. Additionally, male and female nervous system FAAH-restricted (FAAH-NS) (Cravatt et
al., 2004) mice backcrossed onto a C57BL/6J background for at least 13 generations were used.
FAAH (+/-) littermates were used as controls, because they express wild type levels of AEA and
non-cannabinoid fatty acid amides (FAAs) (Cravatt et al., 2001). Lastly, male and female CB1 (/-) and CB2 (-/-) mice, along with respective matched CB1 (+/+) and CB2 (+/+) littermates were
used to determine receptor mechanisms of action. All genetically modified mice were bred in
the Center Transgenic Colony at Virginia Commonwealth University. The genotype of each
genetically altered mouse was confirmed via rt-PCR. Subjects weighed between 20-30 g and
were housed 4-6 per cage in a temperature-controlled (20-22oC) environment. Mice were
randomly assigned to treatment conditions, although a block design was used to evenly distribute
transgenic and knockout mice, by sex, across treatments. Mice were kept on a 12-h light/dark
cycle with food and water available ad libitum. All animal protocols were approved by the
Virginia Commonwealth University Institutional Animal Care and Use Committee and were in
concordance with the Guide for Care and Use of Laboratory Animals (Institute of Laboratory
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Animal Resources, 1996). After testing was completed, mice were humanely sacrificed by CO2
asphyxiation, followed by cervical dislocation.
Drugs
Phytocannabinoids and acetic acid writhing. THC, CBD, and CBN were obtained from the
National Institute on Drug Abuse (Bethesda, MD, USA). SR141716 (rimonabant) and
SR144528, respective antagonists for CB1 and CB2 receptors, were obtained from National
Institute on Drug Abuse (Bethesda, MD), and ∆9-tetrahydrocannabivarin (O-4395, THCV),
cannabichromene (O-4950, CBC) were supplied by Drs. Raj Razdan and Anu Mahadevan
(Organix Inc, MA, USA).
FAAH and COX inhibition in acetic acid writhing. Diclofenac sodium and naltrexone
HCl were purchased from Sigma-Aldrich (St. Louis, MO). URB597 was purchased from
Cayman Chemical (Ann Arbor, MI). WIN55,212 was purchased from Tocris Bioscience
(Ellisville, MO). Rimonabant (CB1 receptor antagonist) and SR144528 (CB2 receptor
antagonist) were obtained from the National Institutes of Health National Institute on Drug
Abuse (Rockville, MD). Diclofenac, URB597, or OL-135 was given via the subcutaneous route
of administration 60 min before acetic acid administration. In the antagonism studies,
rimonabant (3 mg/kg) and SR144528 (3 mg/kg) were given 70 min before acetic acid, whereas
naltrexone (1 mg/kg) was administered 30 min before acetic acid. Each of these doses and
pretreatment times was based on previous reports from the literature (Compton et al., 1996;
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Lichtman et al., 1996; Rinaldi-Carmona et al., 1996) and from previous studies from our
laboratory . Dose-response curves for URB597 and diclofenac were obtained using at least six
animals at each dose. Mice were given subcutaneous injections of vehicle, diclofenac (3, 10, or
30 mg/kg), or URB597 (1, 3, or 10 mg/kg) and 60 min later were given an intraperitoneal
injection of acetic acid.
FAAH and MAGL inhibition in acetic acid writhing. The MAGL inhibitor JZL184 was
synthesized by our collaborators at TSRI (The Scripps Research Institute) as previously
described (Long et al., 2009a). Male C57Bl/6J mice (6–8 weeks old, 20–26 g) were
intraperitoneally administered JZL184 or vehicle (4:1 v/v PEG300/Tween80) at a volume of 4
ml/g weight (16, 40 mg/kg). In studies assessing dual inhibition of both FAAH and MAGL,
JZL184, PF-3845, and JZL195 were dissolved in 1:1:18 (ethanol:emulphor:saline) vehicle
mixture and the drug was sonicated for up to 3 min. Mice were given a subcutaneous injection
of JZL184 (16 mg/kg), JZL195 (20 mg/kg), PF-3845 (10 mg/kg), or vehicle 120 min before
acetic acid administration. Rimonabant (3 mg/kg) or vehicle was given subcutaneous 10 min
before either drug or vehicle.

FAAH inhibition and LPS-induced allodynia. URB597 (1-10 mg/kg i.p.), gabapentin (330 mg/kg i.p.), and MK886 [(1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,αdimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid sodium salt] were purchased from
Cayman Chemical (Ann Arbor, MI). The dose of MK886 used was shown to antagonize the
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PPAR-α receptor in a previous study (Kehrer et al., 2001). This compound is also known to
antagonize lipoxygenase, which can decrease leukotriene production, an action implicated in
modulating inflammatory pain (Masferrer et al., 2010). OL-135 (1-30 mg/kg i.p.) (Boger et al.,
2005), and PF-3845 (1-10 m/kg i.p.; 0.1-10 µg i.pl.) (Ahn et al., 2009) were synthesized as
described previously. THC, rimonabant (CB1 receptor antagonist) and SR144528 (CB2 receptor
antagonist) were obtained from the National Institute on Drug Abuse (Bethesda, MD). 5’Iodoresiniferatoxin (IRTX; TRPV1 receptor antagonist) was purchased from LC Laboratories
(Woburn, MA) and used at a concentration previously described to antagonize TRPV1 receptors
(Wahl et al., 2001). The aforementioned drugs were dissolved in a vehicle consisting of ethanol,
alkamuls-620, and 0.9% saline in a ratio of 1:1:18. Naltrexone HCl was purchased from SigmaAldrich (St. Louis, MO) and dissolved in 0.9% saline. For all systemic injections, the
intraperitoneal (i.p.) route of administration was employed, using an injection volume of 10 µl/g
body weight. Gabapentin and OL-135 were administered 1 h before testing. THC, PF-3845, and
URB597 were administered 2 h before testing. For the receptor antagonist experiments,
rimonabant (3 mg/kg i.p.), SR144528 (3 mg/kg i.p.), MK886 (3 mg/kg i.p.), IRTX (0.5 mg/kg
i.p.), or naltrexone (1 mg/kg i.p.) was administered 10 min prior to the administration of the
FAAH inhibitors/analgesic compounds. For experiments evaluating local effect of FAAH
inhibition, PF-3845 was administered via the intraplantar (i.pl.) route of administration into
either the LPS-treated paw or the saline-treated control paw 2 h prior to testing, using a total

24

volume of 5 µl. The nomenclature of receptors and ligands follows the Guide to Receptors and
Channels (GRAC) (Alexander et al., 2008).
Acetic Acid Stretching Model
The acetic acid stretching test (Koster et al. 1959) was employed to evaluate visceral
nociception. A total of 6-10 naive mice was used per condition in each experiment. For each
desired concentration analyzed, subjects were given a subcutaneous (s.c.) injection of drug or
vehicle 60 min (phytocannabinoid study) and 120 min (FAAH and MAGL inhibition studies)
before an intraperitoneal (i.p.) injection of 0.6% acetic acid. In studies examining the
cannabinoid receptor mechanism of action, rimonabant (3 mg/kg), SR144528 (3 mg/kg), or
vehicle was administered through the i.p. route of administration 10 min before the agonist or
vehicle. All injections were given in a volume of 10 µl/g body weight. After administration of
acetic acid, the subjects were placed in clear cages (11 x 7 x 5 in) and allowed time to acclimate
for 3 min prior to being scored for abdominal stretches during a 20 min observation period.
Stretching was defined as body contortions, belly pressing, and extension of the hind limbs from
which visceral nociception was inferred.

Inflammatory pain model
Inflammatory pain was induced by injecting lipopolysaccharide (LPS) from Escherichia coli
026:B6 Sigma (St. Louis, MO) (Naidu et al., 2010) in 20 µl of physiological saline into the
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plantar surface of one hind paw of each mouse (Kanaan et al., 1996). Saline was administered
into the opposite hind paw. Thus, each mouse served as its own control, thereby reducing the
total number of mice required.
Animals were tested for mechanical allodynia 24 h post LPS administration using calibrated
von Frey filaments, ranging from 0.16 g - 6.0 g (Stoelting, Wood Dale, IL), as described
previously (Kinsey et al., 2010). At 23 h after LPS administration, mice were placed into
Plexiglas cylinders on an elevated wire mesh screen, allowing access to each hind paw by the
filaments. Mice were allowed to acclimate to the test apparatus for 60 min prior to testing. Paw
withdrawal threshold was determined by using the “up-down” method (Chaplan et al., 1994).
The plantar surface of each paw was stimulated 5 times each and a positive response was scored
if each mouse clutched, lifted, or fluttered the paw upon 3 of 5 stimulations. The thickness of the
LPS-treated and saline-treated paws was measured both before and 24 h after LPS injection,
using digital calipers (Traceable Calipers, Friendswood, TX) and expressed to the nearest ± 0.01
mm (Naidu et al., 2010). The 24 h paw thickness values were measured immediately after
allodynia assessment.
Tail withdrawal assay
Each mouse was placed into a small pouch created from absorbent under pads with the
tail extending from the end of the pouch. Mice were loosely held in the pouch while their tails
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were immersed into the water bath maintained at 52oC. The latency for each mouse to withdraw
its tail from the water (tail-flick) within a 10 s cutoff time was tabulated.
Intrathecal injections
Intrathecal injections were conducted the day of the study. Briefly, mice were held
firmly under an absorbent cloth with their lower lumbar region exposed. The lumbar region (L4L6) was located in reference to the hip placement. Mice were then injected with drug or vehicle
in a total volume of 5 µl using 50 µl hamilton syringes. Correct injections were noted after
needle penetration if the subject tail flared.
Stereotaxic i.c.v. surgeries
ICV surgeries were conducted the day before allodynia testing to allow for wound
healing and recovery from anesthesia. Briefly, mice were anesthesized under isoflurane or given
pentabarbitol (45mg/kg; i.p.). Mice were then placed on the digital stereotaxic instrument
(Stoelting) and immobilized using earbars and a muzzle with their teeth inserted into the muzzle
stabilizer (Franklin & Paxinos, 1997). An incision was made in the scalp to expose bregma. A
peroxide soaked swab was used to remove the surrounding layer of brain film so that bregma is
clearly exposed. Next, a hole (2 mm depth) was punctured into the lateral ventricle using
coordinates (-1.0, -0.6) of bregma targeting the lateral ventricles (Allen mouse brain atlas). Mice
were then allowed to recover overnight in their home cages. The day after surgery mice were
injected with drug or vehicle in a total volume of 5 µl using 50 µl hamilton syringes.
27

Extraction and Quantification of Endocannabinoids by LC/MS/MS
AEA and 2-AG levels were quantified in the whole brain, whole spinal cord, and paw
tissue of male C57BL/6J mice treated with a systemic dose of PF-3845 (10 mg/kg, i.p.) or local
dose (1.0 µg, i.pl.) as described above. Two hours after drug or vehicle administration, the mice
were decapitated and tissues were harvested. All tissue samples were snap frozen in liquid
nitrogen and stored at −80°C until the endocannabinoids were extracted.
On the day of extraction, tissues were weighed and homogenized with 1.4 ml
chloroform/methanol (2:1 v/v containing 0.0348 mg PMFS/ml) after the addition of internal
standards to each sample (2 pmol AEA-d8 and 1 nmol 2-AGd8) (Kinsey et al., 2009a).
Homogenates were then mixed with 0.3 ml of 0.73% w/v NaCl, vortexed, and then centrifuged
for 10 min at 4,000 rpm (4°C). The aqueous phase plus debris were collected and extracted two
more times with 0.8 ml chloroform. The organic phases from the three extractions were pooled,
and the organic solvents were evaporated under nitrogen gas. Dried samples were reconstituted
with 0.1 ml chloroform and mixed with 1 ml ice-cold acetone. The mixtures were then
centrifuged for 5 min at 3,000 rpm and 4°C to precipitate the proteins. The upper layer of each
sample was collected and evaporated under nitrogen. Dried samples were reconstituted with 0.1
ml methanol and placed in autosampler vials for analysis. LC/MS/MS was used to quantify
AEA and 2-AG. The mobile phase consisted of (10:90) water/methanol with 0.1% ammonium
acetate and 0.1% formic acid. The column used was a Discovery HS C18, 4.6×15 cm, 3 μm
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(Supelco, PA). The mass spectrometer was run in Electrospray Ionization, in positive mode.
Ions were analyzed in multiple-reaction monitoring mode, and the following transitions were
monitored: (348>62) and (348>91) for AEA; (356>62) for AEAd8; (379>287) and (279>269)
for 2-AG; and (387>96) for 2AG-d8 as described previously (Kinsey et al., 2009a). A
calibration curve was constructed for each assay based on linear regression using the peak area
ratios of the calibrators. The extracted standard curves ranged from 0.03 to 40 pmol for AEA
and from 0.05 to 64 nmol for 2-AG.

Motor Impairment
In an effort to assess motor impairment, subjects were pretreated 60 min (6-8 mice per group)
with a subcutaneous (s.c.) injection of THC (1-50 mg/kg). Each mouse was then placed in a
clear Plexiglas box (17.5 x 8.5 in) situated in a sound attenuating chamber that contained an
indirect filtered light source and fans for air circulation. Locomotor activity was recorded using
Fire-i digital camera software (Unibrain Inc, San Ramon, CA) web camera that was located
above the activity box and behavior was analyzed using the AnyMaze Software (Stoelting, Wood
Dale, IL) as described previously (Schlosburg et al., 2009a).
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Binding assay
Radioligand binding was performed following the method of (Devane et al., 1988) and
modified by (Compton et al., 1993). In brief, binding was initiated by the addition of 75 μg
whole rat brain protein to silanized tubes containing [3H]-CP-55,940, a potent synthetic
cannabinoid analog, (139.6 Ci/mM NEN, DuPont, Boston, MA) and sufficient volume of buffer
A (50mM Tris-HCl, 1 mM Tris-EDTA, 3mM MgCl2, and 5 mg/ml fatty acid-free BSA, pH 7.4)
to bring the total volume up to 0.5 ml. Unlabelled (cold) CP-55,940 (1 uM) was used to assess
non-specific binding. CP-55,940 was suspended without evaporation, in buffer A from 1 mg/ml
ethanolic stock, as were all cannabinoid constituents. After adding tissue, the reaction mixture
was incubated at 30oC for 60 min. Saturation experiments were conducted with 8 concentrations
of [3H]-CP-55,940 ranging from 30 nM to 10 uM. Binding was terminated by the addition of 2
ml ice-cold buffer B (50 mM Tris-HCl, and 1 mg/ml BSA, pH 7.4), and vacuum filtration
(Millipore, Bedford, MA) through pretreated (>4 hr, 0.1% solution of PEI, pH 7.4) GF/C glassfiber filters (2.4 cm, Baxter, McGaw Park, IL). The reaction tubes were then rinsed once with 2
ml and twice with 4 ml of ice-cold buffer B. Before radioactivity was quantified by liquid
scintillation spectrometry, the filters were incubated in 4 ml Budget-Solve (RPI Corp., Mount
Prospect, IL) scintillation fluid, and shaken for 60 min. All assay conditions were conducted in
triplicate, and the results reflect three independent experiments.
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Data analyses
Abdominal stretching. The total number of abdominal stretches was tabulated for each
subject and ED50 values were calculated using least squares linear regression. Data were
analyzed using one-way and two-way ANOVA. Post hoc analyses were conducted with the
Tukey test or Dunnett’s test in dose-response experiments. All differences were considered
significant at p < 0.05. The Ki values for the binding assay were generated from the Radlig
Ligand program from the Kell software package version 6 for Windows, (Biosoft, Milltown, NJ).
Isobolographic analysis for dual inhibition. Isobolographic analysis was used to determine
the nature of the drug interactions, as described previously (Tallarida, 2000). The dose of
diclofenac required to elicit a 50% effect was plotted on the abscissa, and the isoeffective dose of
URB597 was plotted on the ordinate. The theoretical additive effect of the two drugs was
represented by the straight line connecting the two points. If the experimentally determined data
points and their confidence interval lie on this line, the drug effects are considered additive. If the
points lie below this line, the interaction is considered to be superadditive (synergistic); however,
if they lie above the line of additivity, the interaction is defined as subadditive (antagonistic). To
determine whether the interaction between two drugs was synergistic, additive, or antagonistic,
the theoretical additive ED50 value of the two drugs combined (referred to as Zadd) was
calculated from the dose-response curves of each drug administered individually, in which the
combination is assumed to equal the sum of the individual effects of each drug. The experiment
ED50 value of the two drugs in combination (referred to as Zmix) in which the two drugs were
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summed at each concentration was then determined by linear regression. The statistical
difference between Zadd (the theoretical ED50 value) and Zmix (the experimental ED50 value)
were analyzed using Fisher’s test. These calculations were performed using the program of
Pharm Tools Pro (version 1.20; The McCary Group Inc., Elkins Park, PA), based on Tallarida
(2000). p < 0.05 were considered significant.
LPS-induced allodynia. The dependent measures included changes in paw edema (24 h baseline paw thickness values) and mechanical paw withdrawal thresholds 24 h after LPS. All
data are reported as mean ± SEM and were analyzed using one-way analysis of variance
(ANOVA). Dunnett’s test was used for post hoc analysis in the dose-response experiments to
compare the effects of each drug dose to those of vehicle. Tukey-Kramer post hoc analysis was
used for all tests comparing different treatment groups, as well as genotype distinctions.
Differences were considered significant at the p < 0.05 level.
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Chapter 3:

Phytocannabinoids assessment in the blockade of acetic acid induced
abdominal stretching

The first goal of this dissertation was to investigate the effect of prevalent phytocannabinoids
in commonly used mouse models of pain. To date over 70 phytocannabinoid constituents have
been identified, however the pharmacological effect of several remain unknown. THC is well
established to produce analgesia in various models of pain. However, orally administered CBD
was inactive in the acetic acid stretching model and CBN was only effective at high
concentrations (Sanders et al., 1979; Sofia et al., 1975; Welburn et al., 1976). Neither CBC nor
THCV has been characterized in the acetic acid abdominal pain model.
Briefly, male ICR mice were given a subcutaneous pretreatment (60 min) of THC, CBC,
CBN, CBD, or THCV then placed back in their homecages. After the 60 min pretreatment, mice
were injected intraperitoneally with acetic acid and placed in observation chambers for a 3 min
acclimation period. Abdominal stretching was then recorded for 20 min beginning at the end of
the acclimation period. The concentration of acetic acid was chosen based on our studies that
0.6% acetic acid resulted in robust abdominal stretching in mice (Figure 2A). Additionally, the
observation and scoring window was chosen based on our studies showing that the peak
abdominal stretching response rate takes place between 3 and 23 minutes (Figure 2B).
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Figure 2. Increasing concentrations of acetic acid significantly increases abdominal stretching
in mice (A). 0.6% acetic acid produces peak abdominal stretching effects between 3 min and 23
min after intraperitoneal administration (B). Data represents the mean ± SEM abdominal
stretching. n=6 mice per group.
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3.1 THC dose-dependently blocks acetic acid induced stretching through a CB1 receptor
mechanism of action
To determine the effect of phytocannabinoids on abdominal stretching, mice were pretreated
in this first study with ∆9-THC (0.03-5.0 mg/kg; s.c.) then placed in observation boxes and
observed for a total of 23 minutes. The total number of stretches was plotted on the Y-axis
(ordinate). In a follow up study mice were also tested for locomotor activity to assess whether
hypomotility may have contributed to decreases in abdominal stretches. As shown in Figure 3,
∆9-THC dose-dependently suppressed abdominal stretching, with an ED50 value of 1.1 mg/kg
(95% confidence interval 0.8–1.6 mg/kg). This drug was considerably less potent in decreasing
locomotor activity than in producing antinociception. Its ED50 value in suppressing locomotor
activity was 7.7mg/kg (95% confidence interval 4.2–14.3 mg/kg) (see Table 4). ∆9-THC was 8.5
(95% confidence interval: 3.4–20.6) fold more potent in eliciting antinociception than in
decreasing locomotor activity. Based on these results, we employed 3 mg/kg ∆9-THC to
evaluate the underlying receptor mechanism of action, as this dose did not significantly interfere
with locomotor activity after a 60 min pretreatment time compared to vehicle (Table 4).
Rimonabant, but not SR144528, significantly blocked THC’s antinocicpetive effects [F (3, 22) =
37.1, p < 0.0001], indicating a CB1 receptor mechanism involvement (Figure 4A).
Administration of either rimonabant or SR144528 alone did not significantly affect abdominal
stretching behavior (Figure 4B).
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Figure 3. Subcutaneous administration of ∆9-THC reduced abdominal stretching in a dosedependent manner; ED50 (95% confidence interval) value = 1.1 mg/kg (0.8–1.6). Each data
point represents 6–8 mice. **p < 0.01 compared with vehicle. Data reflect the mean ± SEM
number of abdominal stretches during the 20 min observation period.
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Table 4. Evaluation of ∆9-THC in spontaneous locomotor activity behavior. Mice were given
a subcutaneous injection of various concentrations of ∆9-THC and evaluated 60 min later for
locomotor activity for a total of 20 min. Data are represented as the mean ± SEM
Percentage of time spent immobile or total distance traveled, n = 6 mice per group.
% Time Immobile Total Distance Traveled (m).

%Time Immobile

Total Distance Traveled (m)

Vehicle

21.1 ± 4.2

46.54 ± 5.66

1.0

11.2 ± 2.2*

41.79 ± 2.63

3.0

21.5 ± 5.0

43.59 ± 4.70

10.0

37.6 ± 9.2

45.86 ± 7.76

50.0

49.0 ± 6.8*

35.34 ± 3.61*

17.6 ± 2.9

39.02 ± 7.75

∆9-THC (mg/kg)

CBN (mg/kg)
50.0
*p < 0.05 vs vehicle treated mice
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Figure 4. The antinociceptive
effects of ∆9-THC in the acetic
acid

model

of

visceral

nociception

are

mediated

through

CB1

receptor

a

mechanism of action. (A) The
CB1

receptor

antagonist,

rimonabant (Rim; 3.0 mg/kg,
i.p.), but not the CB2 receptor
antagonist, SR144528

(SR2;

3.0 mg/kg, i.p.), blocked the
antinociceptive effects of ∆9THC (3 mg/kg, s.c.). # indicates
significant

difference

from

Vehicle (Veh)/∆9-THC control
p

<

0.01;

**Significant

difference from Vehicle/Vehicle control p < 0.01. (B) Neither rimonabant nor SR144528 given
alone affected acetic acid-induced abdominal stretching. n= 6–8 mice/group. Data reflect the
mean±SEM number of abdominal stretches.
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3.2 Evaluation of other phytocannabinoids in the acetic acid abdominal stretching model

The question of whether other prevalent naturally occurring marijuana constituents also
possess antinociceptive properties was addressed by administering either vehicle, CBC, CBD,
CBN, or THCV, 1 h before the administration (i.p.) of acetic acid. As shown in Figure. 5A,
CBN produced a significant reduction in acetic acid-induced abdominal stretching, [F(6, 35) =
9.5, p < 0.001]. According to post hoc analysis, CBN produced significant antinociceptive
effects at 50 mg/kg (p < 0.01), but not at 20mg/kg (p = 0.27). In contrast, high doses of CBC or
CBD did not produce antinociceptive effects in this assay. CBN (50 mg/kg) failed to inhibit
locomotor activity when administered 60 min prior to recording spontaneous activity (Table 4).
As shown in Figure 5B, the antinociceptive effects of CBN (50 mg/kg) were blocked by
rimonabant, but not by SR144528 [F(3, 24)=17.5, p < 0.001]. While THCV (50 mg/kg)
administered alone had no effect on the frequency of stretching behavior (Figure 6), it blocked
the antinociceptive effects of ∆9-THC, [F(3, 26) = 9.52, p < 0.001].
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Figure 5. Evaluation of prevalent marijuana constituents in the acetic acid abdominal stretching
model. (A) The marijuana constituents, CBC and CBD, did not produce antinociceptive
effects. However, CBN (50 mg/kg) significantly suppressed the stretching response compared to
vehicle (Veh), **p < 0.01 vs. Vehicle. (B) The CB1 receptor antagonist, rimonabant (Rim), but
not by the CB2 receptor antagonist, SR144528 (SR2), significantly blocked the antinociceptive
effects of CBN (50 mg/kg). **p < 0.01 vs. Veh/Veh, and #p < 0.01 vs. Veh/CBN. n= 6–10
mice/group. Data reflect the mean ± SEM abdominal stretches.
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Figure 6. Delta 8-tetrahydrocannabivarin (THCV, 50 mg/kg, s.c.) had no effects on its own, but
blocked the antinociceptive effects of THC (3.0 mg/kg, s.c.). **p < 0.01 vs. Veh/Veh group. #p
< 0.05 vs. Veh/THC. n= 6–8 mice/group. Data reflect the mean ± SEM abdominal stretches.
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3.3 Receptor binding affinity of CBN, THC, and THCV

In order to determine whether the prevalent phytocannabinoids were displaying their
effects through cannabinoid receptors we conducted binding displacement curves. The binding
affinities for THC, CBC, CBD, CBN, and THCV to the cannabinoid receptor were measured by
the displacement curve of tritiated CP-55,940 ([3H]-CP-55,940). These data are summarized in
Table 5. THC and THCV bound to the CB1 receptor with equal affinity (Ki values ± SEM =
47.7± 4.6 nM and 46.3 ± 6.0 nM, respectively) as illustrated by the similarity of their
displacement curves (Figure 7). Rat brains were used due to the increased amount of tissue,
however it is noted that there is 99% homology between rat and mouse brains (Chakrabarti et al.,
1995) . CBN also displaced [3H]-CP-55,940 binding (129.3 ± 12.9 nM), but its affinity was 2–3
fold lower than the affinity of THC at the CB1 receptor. Neither CBD nor CBC showed any
affinity for the CB1 receptor (Ki values > 10,000 nM).
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Figure 7. Activity of prevalent phytocannabinoids at rat cannabinoid receptor type 1. The
affinity of ∆9-THC was determined for rat CB1 receptor (filled circles/solid line), THCV (open
circle/solid line), CBN (filled triangle/dash-dotted line), CBD (open triangle/dashed line), and
CBC (filled square/dashed line). Details for competition binding experiments are described in
the methods section. The points on the graph represent the mean±SEM of three independent
experiments with duplicate wells on each plate. The data were normalized to the signal in the
absence of unlabeled competitor (defined as 100%) and in the presence of excess unlabeled CP55,940 (defined as 0%).
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Table 5. Ki-values for displacement of [3H]-CP-55,940 from mouse whole brain. ∆9-THC,
CBN, and THCV displaced [3H]-CP-55,940 in the nanomolar range. However, CBD and CBC
lacked affinity for the receptor. n = 3 brains per drug.

44

3.4 Discussion: Phytocannabinoids reduce visceral nociception
In previous years less attention was given to marijuana and its potential use as an
analgesic compound, in part, due to its psychoactive properties, which are primarily caused by
the actions of ∆9-THC. However, other constituents of marijuana may have analgesic properties
with minimal psychoactive effects compared to ∆9-THC. The results of the present study
demonstrate that while ∆9-THC and CBN elicited antinociception in the acetic acid abdominal
stretching model, other phytocannabinoids (i.e., CBD, CBC, and THCV) did not affect
abdominal stretching when given alone, and THCV actually inhibited the antinociceptive effects
of ∆9-THC. Additionally, the present study determined that the antinociceptive effects of ∆9THC and CBN were mediated through a CB1 receptor mechanism of action.
The results obtained in the present chapter are consistent with the view that ∆9-THC is
the major phytocannabinoid present in marijuana that produces antinociception in the acetic acid
abdominal stretching test. Previous studies reported that ∆9-THC dose-dependently suppressed
abdominal stretching in the p-phenylquinone test (Dewey et al., 1972; Sanders et al., 1979),
formic acid test (Welburn et al., 1976), and acetic acid writhing test (Sofia et al., 1975) in mice,
with ED50 values ranging between 1.2 and 4.2 mg/kg. In agreement with earlier work, THC
dose-dependently reduced abdominal stretching, though we used the s.c. route of administration
and the earlier work administered the drug via gavage. The finding that rimonabant completely
blocked the antinociceptive effects of ∆9-THC indicates a CB1 receptor mechanism of action.

45

A major goal of the present chapter was to also investigate other prevalent cannabinoid
constituents of marijuana in the acetic acid model of visceral pain. These compounds closely
resemble ∆9-THC structurally and, in some cases, bind to CB1 receptors. Emphasis has been
drawn away from naturally occurring compounds, due to their relative low abundance in
marijuana compared to ∆9-THC (ElSohly et al., 2000). CBN (50 mg/kg) suppressed abdominal
stretching through a CB1 receptor mechanism of action. Sofia et al. (1975) also found that high
concentrations of CBN were required to elicit antinociceptive effects after gavage administration.
Although the binding affinity of ∆9-THC is 2–3 folds greater than the binding affinity of CBN,
∆9-THC is at least fold 50 fold more potent than CBN in producing antinociception. However,
the relationship between binding affinity and in vivo activity of the cannabinoids is not linear, but
takes on a logarithmic function (Compton et al., 1993). For example, CBN was 90–250 fold less
potent than ∆9-THC in eliciting ∆9-THC-like discriminative cues in pigeons (Jarbe et al., 1977).
Thus, the fact that higher doses of CBN than ∆9-THC are required to elicit antinociceptive
actions in this visceral pain model is consistent with its low binding affinity for the CB1 receptor
compared to the affinity of ∆9-THC.
These experiments are the first to our knowledge to examine the effectiveness of CBC to
displace [3H] CP-55,940 at the cannabinoid receptor. However, this phytocannabinoid which is
also a aromatic hydrocarbon containing 21 carbons, did not bind to CB1 receptors and did not
produce antinociceptive effects in the acetic acid model of visceral nociception. The lack of
antinociceptive efficacy of CBD in the acetic acid stretching model is consistent with previous
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reports (Sanders et al., 1979; Welburn et al., 1976) (Sofia et al., 1975). Moreover, the poor
affinity of CBD to the CB1 receptor was consistent with previous research (Showalter et al.,
1996; Thomas et al., 2007). Although THCV, the propyl homologue of ∆9-THC had equivalent
binding affinity as ∆9-THC, it failed to elicit antinociceptive effects at doses up to 50 mg/kg.
This compound has been reported previously to have competitive antagonist effects with ∆9-THC
at low concentrations, though it elicited agonist activity at high intravenous doses (Pertwee et al.,
2007). Indeed, we report that a high dose of THCV (i.e., 50 mg/kg) significantly antagonized the
antinociceptive effects of ∆9-THC (3 mg/kg), further supporting the notion that THCV is a
naturally occurring CB1 receptor antagonist.
Because cannabinoids are known to elicit hypomotility, which would confound
interpretations of the behavioral data in the acetic acid-induced stretching assay, we examined
the effects of each active drug on locomotor behavior. ∆9-THC did not impair mobility at doses
less than 50 mg/kg, suggesting that the dose range used in the acetic acid stretching test did not
provoke motor disturbances. Additionally, CBN did not affect mobility at the dose that produced
antinociception. Traditionally, cannabinoid agonists have been shown to produce reductions in
locomotor activity (Hohmann et al., 2005), which is one of the hallmarks of ∆9-THC. The
increased potency of ∆9-THC in producing antinociception compared to its potency in producing
locomotor suppression may be attributed to the fact that the acetic acid assay is particularly
sensitive to antinociceptive agents.
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CB1 selective and CB2 selective antagonist (rimonabant and SR144528 respectively)
failed to increase abdominal stretching when administered alone, suggesting that acetic acidinduced stretching is not affected by endocannabinoid tone. Interestingly, there are considerable
in vitro and in vivo data suggesting that endocannabinoids are produced and released on demand
(Jung et al., 2005; Matias et al., 2006; Patel et al., 2003). Walker et al. (1999) showed that the
electrical stimulation of the periaqueductal gray (PAG) area as well as formalin injected
intradermally into the hind paws elevated ananadamide levels in the PAG, supporting the role
that endocannabinoids are released in response to pain sensing pathways. In addition, Hohmann
et al. (2005) demonstrated that intracerebral administration of inhibitors of endocannabinoid
metabolizing enzymes into the PAG potentiated stress-induced antinociception and led to
concomitant release of endocannabinoids within this brain region.
In summary, our results show that ∆9-THC dose-dependently suppressed the frequency of
acetic acid induced stretching. Its antinociceptive effects were shown to be mediated through a
CB1 receptor mechanism of action, without any indication of CB2 receptor involvement. The
only other naturally occurring constituent of marijuana evaluated that produced antinociception
was CBN, but the required dose (i.e., 50 mg/kg) was substantially higher than the minimal dose
of ∆9-THC that produced antinociception (i.e.,1mg/kg). CBD, CBC, and THCV failed to produce
antinociception in the acetic acid test. Conversely, while THCV given alone did not affect
visceral nociception, it antagonized the antinociceptive actions of ∆9-THC when both drugs were
given in combination. Although this pattern of findings raises the provocative possibility
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that other components of this plant can augment (e.g., CBN) or reduce (e.g., THCV) the
antinociception actions of ∆9-THC, it should be noted that marijuana contains a far lower
abundance of CBN (0.24–1.44%) than ∆9-THC (4–20%) (ElSohly et al., 2000). Additionally,
the percentage of THCV is considerably low and varies in samples of marijuana of different
origins (Brenneisen and elSohly, 1988). Thus, these specific constituents would not be expected
to play a substantial role in marijuana’s pharmacological effects. On the other hand, these results
suggest that there is potential to develop medications containing various concentrations of
specific phytocannabinoids to optimize therapeutic effects (e.g., antinociception) and minimize
psychomimetic effects. The results of the present chapter further support the notion that ∆9-THC
is the predominant constituent of marijuana responsible for eliciting antinociceptive effects and
indicate that CB1 receptors play a predominant role in mediating these effects. Moreover, these
data suggest that other phytocannabinoids may also be used to modulate the analgesic effects of
∆9-THC.
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Chapter 4:

Evaluation of the endocannabinoid systems role in modulating visceral
nociception in the acetic acid abdominal stretching model

4.1 Global activation of the CB1 receptor reduce acetic acid abdominal stretching

In chapter 3, we showed that phytocannabinoids mediated their antinociceptive effects in
the visceral pain model through the CB1 receptor, therefore this series of experiments were
designed to examine specific components of the endocannabinoid system and its role in
modulating visceral nociception. The first objective was to use a selective CB1 and CB2
receptor agonist in an effort to determine cannabinoid receptor involvement.
In the first set of experiments, mice were pretreated (1 h) with either the selective CB1
agonist (ACEA) (Hillard et al., 1999), or the selective CB2 agonist (O-3223) (Kinsey et al.,
2011). Afterward mice were given an i.p. injection of 0.6% acetic acid, placed in observation
chambers for a 3 min acclimation period, and then scored for abdominal stretching for a total of
20 min.
As illustrated in Figure 8A, ACEA (10 mg/kg) significantly attenuated abdominal
stretching (p< 0.01). However, the selective CB2 agonist at the low and high dose tested did not
affect abdominal stretching, suggesting that this receptor does not play a role in the
antinocicpetive effects produced by cannabinoids. To confirm the CB1 receptor mechanism , we
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employed the selective CB1receptor antagonist, rimonabant. Mice were pretreated with either
vehicle or rimonabant (3 mg/kg) for 10 min, followed by a subcutaneous administration of
ACEA (10 mg/kg). The antinociceptive effects produced by ACEA in the abdominal stretching
model were significantly blocked by the pretreatment of rimonabant (p<0.01) Figure 8B.
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Figure 8. Assessment of the
selective CB1 agonist, ACEA
and the selective CB2 agonist
(O-3223) on abdominal
stretching. (A) ACEA and not
O-3223 reduced abdominal
stretching (10 mg/kg, s.c). (B)
Rimonabant (3 mg/kg, s.c.)
blocked the antinocicpetive
effects of ACEA. n =6-8 mcie
per group. **p < 0.01 versus
vehicle, ##p < 0.01 versus
vehicle/ACEA. All data
represent the mean ± SEM
abdominal stretching
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4.2 FAAH knockout mice display an antinocicpetive phenotype in the acetic acid abdominal
stretching test
While direct-acting cannabinoid receptor agonists such as ACEA possess analgesic
properties, their psychomimetic side effects have dampened enthusiasm for their development as
therapeutic agents. Conversely, increasing endogenous cannabinoid levels by blocking FAAH
represents an attractive alternate approach to elicit antinociception, but without eliciting
cannabimimetic effects (Cravatt et al., 2001; Gobbi et al., 2005). Deletion of the FAAH gene
increases levels of anandamide, accompanied with CB1 receptor-mediated hypoalgesic
phenotypes in models of acute and inflammatory pain (Cravatt et al., 2001). Hence, our aim was
to first assess the effect of genetic deletion of FAAH in the abdominal stretching model and
determine the receptor mechanism of action underlying the antinociceptive effects caused by
FAAH deletion. Unlike our previous experiments, in these studies we used an inbred strain of
male mice (C57BL/6) since our genetically modified mice are backcrossed on this background
strain.
FAAH (-/-) mice displayed a significant attenuation of acetic acid-induced nociception, t
(10) = 5.0, p< 0.001 Figure 9A. Rimonabant and SR144528, were used to ascertain the
involvement of CB1 and CB2 receptors in the antinociceptive phenotype exhibited by FAAH (-/) mice. Rimonabant (3 mg/kg), but not SR144528 (3 mg/kg), significantly blocked the
antinociceptive phenotype of FAAH (-/-) mice, F(2,33) = 6.1, p< 0.01 (Figure 9B). As we found
previously in the outbred ICR strain of mice, the cannabinoid receptor antagonists administered
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by itself to wild type mice did not alter the number of abdominal stretches compared with
vehicle-treated control mice. These results suggest that the antinociceptive phenotype of FAAH
(-/-) mice in the acetic acid model of visceral nociception is mediated through a CB1
cannabinoid receptor. Endocannabinoids are synthesized locally on demand from phospholipid
precursors and regulate homesostasis. However, rimonabant or SR144528 administered alone
did not alter abdominal stretching suggesting that endocannabinoid tone is not mediating the
decrease in abdominal stretching.
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Figure 9. FAAH (-/-) antinociceptive phenotype in the acetic acid model of visceral nociception
is mediated through a CB1 receptor mechanism of action. (A) FAAH (-/-) mice exhibit less
abdominal stretching than FAAH (-/-) mice. n= 8 mice/group. (B) Pretreatment with rimonabant
(SR1; 3 mg/kg s.c.), but not SR144528 (SR2; 3 mg/kg s.c.), prevented the FAAH antinocicpetive
phenotype in acetic acid-treated mice, n = 12 mice/group. ** p < 0.01 compared with respective
control groups; data depicted as means ± S.E.M.
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4.3 FAAH and COX inhibition dose responsively suppress acetic acid abdominal stretching
Our previous study indicated that FAAH (-/-) mice show an antinociceptive phenotype in
the abdominal stretching model. Similar to FAAH knockout mice, wild-type mice treated with
FAAH inhibitors, such as URB597 (Kathuria et al., 2003) or the reversible FAAH inhibitor, OL135 (Lichtman et al., 2004a), were previously shown to elicit hypoalgesic effects in acute models
of pain that were accompanied with elevations of anandamide in the CNS (Lichtman et al.,
2004a). In addition, FAAH inhibitors reduced hypersensitivity to thermal and mechanical
hypersensitivity in neuropathic pain models (Chang et al., 2006; Russo et al., 2007).
Consequently, we examined whether reversible and irreversible FAAH inhibitors would decrease
abdominal stretching in acetic acid induced stretching model. Secondly, we sought to reveal the
receptor mechanism of action for the observed antinociceptive effects of FAAH inhibition. To
accomplish this goal we pretreated mice with the CB1 and CB2 receptor antagonist, rimonabant
or SR144528 respectively, prior to administering each FAAH inhibitor. Additionally, since
FAAH inhibitors have been illustrated to have an opioid receptor mechanism of action (Chang et
al., 2006), we evaluated whether naltrexone, the opioid receptor antagonist, pretreatment would
block the antinociceptive effects of FAAH inhibition.
As shown in Figure 10A, URB597 (3 and 10 mg/kg) significantly reduced acetic acidinduced abdominal stretching, F(3,32) = 14.8, p< 0.001. Additionally, diclofenac sodium (10,
and 30 mg/kg s.c.) significantly attenuated stretching, F(3,16)= 12, p< 0.01. Pretreatment with
rimonabant (3 mg/kg), but not SR144528 (3 mg/kg), significantly blocked the antinociceptive
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effects of URB597 (Figure 10A). Likewise, administration of OL-135 (30 mg/kg), the reversible
FAAH inhibitor produced CB1 receptor-mediated antinociceptive effects in the acetic acid
model, F(3,20)= 19.4, p< 0.001 (Figure 10B). Furthermore, the antinociceptive effects of
URB597 or OL-135 [F(2,30) = 68, p<0.001] were not blocked by the opioid antagonist,
naltrexone (1 mg/kg; see Figure 11).
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Figure 10. Pharmacological inhibition of FAAH reduces acetic acid-induced visceral
nociception through a CB1 receptor mechanism of action. (A) pretreatment with URB597
(URB; 10 mg/kg s.c.), an irreversible FAAH inhibitor significantly reduced the number of
abdominal stretches in acetic acid-treated mice. Pretreatment with rimonabant (SR1; 3 mg/kg
s.c.), but not SR144528 (SR2; 3 mg/kg s.c.), prevented the antinociceptive effects of URB597. n
= 9 mice/group. (B) OL-135 (OL; 30 mg/kg s.c.), a reversible FAAH inhibitor, significantly
attenuated the number of abdominal stretches in acetic acid-treated mice. Pretreatment with SR1
(3 mg/kg s.c.), but not SR2 (3 mg/kg s.c.), prevented the antinociceptive effects of OL-135. n = 6
mice/group. *** p < 0.001 compared with the appropriate control group; ## p < 0.01 compared
with URB-treated group; ### p< 0.001 compared with the OL-treated group.
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Figure 11. Antinociceptive effects of URB597 (10 mg/kg) or OL-135 (30 mg/kg) were not
blocked by naltrexone (1 mg/kg). n = 6 mice/group. Data depicted as means ± SEM abdominal
stretches.
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Previous studies illustrated that coadministration of an NSAID and a synthetic
cannabinoid agonist, WIN55-212 elicited additive analgesic effects in the acetic acid abdominal
stretching model (Ulugol et al., 2006). However, WIN55-212 produces THC-like
cannabimimetic properties such as hypomotility, catalepsy, and hypothermia. However, FAAH
inhibition does not produce these THC like effects. Therefore, we sought to determine if
coadministration of a FAAH inhibitor and COX enzyme inhibitor can act synergistically to
decrease abdominal stretching. NSAIDs are drugs that target cyclooxygenase (COX) enzymes
for which there are two subtypes. COX-1 is constitutively active whereas COX-2 is inducible
(Warner and Mitchell, 2004). However, both subtypes regulate the synthesis of prostaglandins
(Samad et al., 2001) therefore blocking its activity reduces inflammatory responses. However,
chronic use of NSAIDs results in severe gastrointestinal effects such as ulcer formation, thus
COX inhibitors although very effective as analgesics, remain a clinical concern (Wallace, 1996).
Conversely, there may be beneficial gain to treat pain with drugs of different classes in
combination. Combination therapy is beneficial because it can potentiate the desired effects
while diminishing unpleasant side effects associated with certain drugs by reducing the dose of
each drug. Furthermore, it can reduce the chance of developing rapid tolerance to a single class
of drugs. Hence, our next aim was to determine the effect of dual inhibition of FAAH and COX
enzymes. Dual inhibition of both enzyme inhibitors may offer an attractive therapeutic approach
by increasing analgesia and decreasing untoward side effects associated with NSAIDs alone.
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Figure 12. Synergistic effects of FAAH and
COX inhibition. (A) FAAH and COX
inhibition dose-dependently reduced nociceptive
responses, URB597 (1–10 mg/kg s.c.) or
diclofenac sodium (3–30 mg/kg s.c.) compared
with the control groups. ** p< 0.01;*** p<
0.001 (B) dose effect curves for URB597 alone
and in mixtures with diclofenac and (C) dose
effect curves for diclofenac alone and in
mixtures with URB597. Data represents the
means ± SEM abdominal stretches. n=6
mice/group.
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Table 6. Fixed combinations of diclofenac and URB597 produce synergistic analgesic
effects in the acetic acid abdominal stretching model. Predictive additive ED50 values (Zadd)
and experimentally determined ED50 values (Zmix) for mixtures of diclofenac and URB597 in
mice. Doses for each drug in combination at the three different ratios are presented in the first
column. * p < 0.05 as compared with respective Zadd (theoretical value) using the Fisher test.

62

Both URB597 and diclofenac dose responsively reduced acetic acid abdominal stretching
(Figure 12A-C). The ED50 values and 95% confidence limit for URB597 and diclofenac were
2.1 (1.5–2.8) and 9.8 (8.2–11.7) mg/kg, respectively. Shown in Figure 12B are the 1:3, 1:1, and
3:1 combinations of URB597 and diclofenac, with the dose of URB597 plotted on the x-axis.
The dose response curve of URB597 alone is plotted in this graph for comparison. The same
data are also plotted in Figure 12C, with the dose of diclofenac plotted on the x-axis. The dose
response curve of diclofenac alone is also included in this graph for comparison. The plots of the
combination ED50 values for both fixed ratios (total dose) in relation to the ED50 values of the
drugs alone are shown in Figure 13. The isobologram analysis suggests that a synergistic
interaction occurs between URB597 and diclofenac because the experimental point falls
significantly below the line of additivity. The graphic display of synergism is confirmed
mathematically by statistical analysis of the predicted additive ED50 values (Zadd) and
experimentally derived ED50 values (Zmix) shown in Table 6.
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Figure 13. Synergistic interaction between FAAH and COX inhibition. Isobolographic
analysis showing the interactions between diclofenac sodium and URB597 in the mouse acetic
acid-induced abdominal stretching test. The ED50 values for diclofenac and URB597 are
depicted on the x- and y-axes, respectively. The isobole of additivity is shown as a solid line
drawn between the ED50 values of diclofenac and URB597. The experimental ED50 values
with 95% confidence interval of mixtures of URB597 and diclofenac at the fixed-ratio
combinations of 3:1, 1:1, and 1:3 were significantly below the theoretical isoboles of additivity,
indicating a synergistic interaction. n= 6 mice/group.
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4.4 Antinociceptive effects of MAGL inhibition in the abdominal stretching model

Of the two primary endocannabinoid degradative enzymes only FAAH has been
characterized for its role in behavioral effects in vivo. Recently it was discovered that
approximately 85% of 2-AG hydrolysis is attributable to MAGL (Blankman et al., 2007).
Therefore, we sought to determine the effects of inhibiting MAGL in the abdominal stretching
model of visceral nociception. Although several first generation MAGL inhibitors have been
synthesized, their selectivity and efficacy in vivo is limited. URB602 was among the first
enzymes synthesized to target MAGL although it was later demonstrated that it has low potency
(uM range) for MAGL (Makara et al., 2005) and may also target FAAH enzyme. Narachidonoyl maleimide (NAM), another potential MAGL inhibitor was shown to inhibit up to
80% of MAGL, however it also blocked FAAH mediated effects (Blankman et al., 2007).
However, the development of JZL184, a selective MAGL inhibitor shows great selectivity and
efficacy in vivo (Long et al., 2009a). JZL184 selectively blocks MAGL and elevate 2-AG levels
10-fold in the brain. Conversely, JZL184 also inhibits FAAH at high concentrations, but its
inhibition does not significantly elevate AEA levels.
Mice were treated with vehicle or JZL184 (4-40 mg/kg; s.c.) for 120 mins. Afterward,
mice were administered acetic acid (0.6%; i.p.) then placed in observation chambers for 3 min
acclimation period, followed by a 20 min observation period where they were scored for
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abdominal stretching. In a follow-up study, mice were pretreated with rimonabant (3 mg/kg)
followed 10 min later by JZL184 (40 mg/kg) and then scored for abdominal stretching.
JZL184 administration dose-dependently blocked acetic acid induced abdominal
stretching. JZL184 (16 mg/kg and 40 mg/kg) significantly differed from vehicle (Figure 14). In
order to determine whether the analgesic effects of JZL184 were mediated through the CB1
receptor, we pretreated mice with rimonabant followed by JZL184. The medium dose of JZL184
(16 mg/kg) was used to determine this effect since the highest dose resulted in sedative like
effects. Rimonabant (3 mg/kg) significantly blocked abdominal stretches in the acetic acid
stretching model, p < 0.01 versus vehicle. Furthermore, the antinociceptive effect was reversed
with the pretreatment of rimonabant ##p <0.01 (Figure 15).
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Figure 14. JZL Dose Response in acetic acid abdominal stretching model. 2 h pretreatment
with JZL184 dose dependently attenuated the acetic acid abdominal stretches at 16 mg/kg and 40
mg/kg s.c. **p< 0.01 vs Veh. Data represents the mean ± SEM abdominal stretches. n=6 mice
per group.
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Figure 15. Behavioral effects of JZL184. JZL184 produced antinociceptive effects in the
acetic acid abdominal stretching assay of noxious chemical pain sensation (16 mg/kg,
intraperitoneally). **p < 0.01 for vehicle-vehicle-treated mice (filled) versus vehicle-JZL184treated mice (open) ##p< 0.01 for vehicle-JZL184-treated mice versus rimonabant-JZL184treated mice. Data are presented as means ± SEM; n= 6–14 mice per group.

68

4.5. Dual blockade of FAAH and MAGL in the abdominal stretching model

Due to the fact that FAAH inhibition and MAGL inhibition produced antinociceptive
effects in the abdominal stretching model separately, we tested whether dual blockade of both
enzymes would enhance the antinociceptive effect of one alone. Recently, JZL184 was
described as possessing cannabimimetic effects such as hypothermia, catalepsy, and
hypomotility (Long et al., 2009). Conversely, FAAH inhibition does not produce these effects
therefore, inhibiting both FAAH and MAGL may potentiate the antinociceptive effects while
decreasing the cannabimimetic effects produced by MAGL inhibition alone. To accomplish this
objective, FAAH (-/-) mice were treated with JZL184 (16 mg/kg), then assessed in the
abdominal stretching model. Complementary pharmacological studies were also conducted to
confirm dual enzyme inhibited antinociceptive effects. To accomplish this aim, FAAH wild-type
mice were treated with PF-3845, the selective FAAH inhibitor (Ahn et al., 2009), JZL184, or the
dual FAAH/MAGL enzyme inhibitor, JZL195 (Long et al., 2009b). Furthermore, to determine
the receptor mechanism of action, we evaluated the effect of the dual inhibitor in the presence of
rimonabant (3 mg/kg). We hypothesize that dual inhibition of MAGL and FAAH produces an
enhancement of effect in the acetic acid stretching test greater than the sum of inhibiting one
enzyme. C57BL/6J mice were injected with vehicle, JZL184 (16 mg/kg; s.c.), PF-3845 (10
mg/kg; s.c.), or JZL195 (20 mg/kg; s.c.) 2 h prior to the administration of acetic acid (0.6%; i.p.).
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FAAH (-/-) mice which have elevated levels of AEA, show a reduction in abdominal
stretches compared to their wild-type match. Additionally, FAAH (-/-) mice administered
JZL184 show an enhanced antinociceptive phenotype compared to FAAH (-/-) mice alone p
<0.01 (Figure 16). This effect was reversed with rimonabant (3 mg/kg) pretreatment.
Pharmacological inhibition was also assessed. FAAH (+/+) mice treated with PF-3845 or
JZL184 showed a significant reduction in abdominal stretching p<0.01 vs FAAH (+/+) vehicle.
Furthermore, the dual inhibitor JZL195 significantly enhanced the antinociceptive effects
compared to PF-3845 or JZL184 alone. Lastly, we determined that the antinociceptive effect
was mediated through the CB1 receptor mechanism of action, since rimonabant blocked the
antinociceptive effects of JZL195 (Figure 16).
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Figure 16. FAAH (-/-) mice show antinociceptive effects in abdominal stretching model.
Dual blockade of FAAH and MAGL produces enhanced antinociceptive effects in the acetic acid
model of visceral pain sensation through a CB1 receptor mechanism of action. Subjects were
treated with rimonabant (RIM, 3 mg/kg), JZL195 (20 mg/kg), JZL184 (16 mg/kg), or vehicle.
***, p<0.001 vs. FAAH (+/+) vehicle group; ###, p< 0.001 vs. FAAH (-/-), JZL184, and FAAH
(-/-) + JZL184 + RIM. ‡‡‡, p< 0.001 vs. JZL195 + RIM; $$, p < 0.01 vs. JZL184 or PF-3845
(planned comparison). Data are presented as means ± SEM. n= 7–10 mice per group. Data in
this figure were compiled from four different experiments (7-23 mice per group), with each
experiment consisting of 7-8 mice per group.
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4.6 Discussion: Endocannabinoid degradative enzyme inhibition produces antinociception via
CB1 receptor

The first goal of the current chapter in this dissertation was to test the hypothesis that
CB1 receptor activation reduces visceral nociception. Accordingly, we treated mice with
selective CB1 (ACEA) and CB2 agonist (O-3223) and found that only the CB1 receptor agonist
blocked the stretching response. Furthermore, we confirmed the receptor mechanism of action
by pre-treating mice with the selective CB1 antagonist, rimonabant. Rimonabant blocked the
antinociceptive effects of ACEA, implicating that this receptor has a role in the analgesic effects
produced by cannabinoids in the abdominal stretching model. These results are consistent with
previous data where we showed THC’s analgesic effects in the abdominal stretching model are
reversed by rimonabant and not SR144528.
The second goal of this chapter was to determine the effects of indirectly
elevating anandamide levels by genetic deletion of FAAH or pharmacological inhibition of the
FAAH enzyme on abdominal stretching. FAAH (-/-) mice showed an antinociceptive phenotype
when treated with acetic acid. This effect was reversed with rimonabant and not SR144528.
Previous research has also found that FAAH (-/-) mice and mice treated with FAAH inhibitors
possess elevated levels of anandamide in the CNS and periphery that reduce baseline pain
thresholds to noxious thermal and chemical stimuli (Lichtman et al., 2004)(Kathuria et al., 2003).
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In addition, FAAH (-/-) mice possess increased brain levels of fatty acid amides, including Npalmitoyl ethanolamine (PEA) (Cravatt et al., 2001), and N-acyl taurines
(Saghatelian et al., 2006), which could also contribute to the antinociceptive phenotype. PEA
has been revealed to have anti-inflammatory actions in acetic acid test, and formalin test,
(Calignano et al., 2001, LoVerme et al., 2005) which were reversed with SR144528 and not
rimonabant. Thus, it is probable that elevated levels of PEA or other lipid signaling molecules,
in addition to AEA, may contribute to the antinociceptive phenotype observed in FAAH (-/-)
mice or mice treated with FAAH inhibitors. The antinociceptive effects in FAAH (-/-) mice
were mediated via a CB1 and not a CB2 mechanism of action as previous studies demonstrated
(Lichtman et al., 2004). Our pharmacology studies revealed that wild-type mice when treated
with either a reversible FAAH inhibitor (OL-135), or an irreversible FAAH inhibitor (URB597)
displayed a reduction in the total number of abdominal stretches which were reversed by CB1
antagonism. Conversely, we did not find any involvement of the opioid system in the
antinociceptive effects produced by FAAH inhibition as previously illustrated (Chang et al.,
2006). These differences may be due to the fact that these previous studies used rats as subjects
whereas we assessed these effects in mice. Furthermore, stress induced by the spinal nerve
ligation or mild thermal injury model may result in the release of endorphins and subsequent
activation of the opioid system.
Due to the fact that NSAIDS and FAAH inhibitors can reduce abdominal stretching
independently, we investigated whether blockade of COX and FAAH simultaneously would
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enhance the antinociceptive effect of one alone. COX regulates the production of
proinflammatory agents such as prostaglandins which have been shown to induce abdominal
stretches (Matsumoto et al., 1998) on their own. Therefore, inhibiting COX should reduce
abdominal stretching. Diclofenac, a COX inhibitor dose dependently suppressed the abdominal
stretching response, although the dose that blocked abdominal stretching was 4 fold higher than
the dose of the FAAH inhibitor in this model. Nevertheless, these data suggest that FAAH
inhibition is as effective as a therapeutically used NSAID in the acetic acid stretching model.
Since both COX and FAAH inhibition reduced stretching when administered alone, we
determined whether these two agents would have an enhancement of effect when administered
together. Mice were treated with equipotent doses of diclofenac and URB597 in combination in
a dose response study. Isobolographic analysis demonstrated that simultaneous administration of
FAAH and COX produced synergistic interactions thereby illustrating the potential of
combination therapy in the treatment of visceral pain.
Although FAAH has been highly characterized and there are several investigative tools to
assess its value, the other primary enzyme inhibitor MAGL has not been investigated in in vivo
assays. The reason for lack of data on MAGL is that there is a limited availability of selective
inhibitors for MAGL. URB602 was the first reported MAGL inhibitor able to elevate 2-AG
levels although it also targeted FAAH (Comelli et al., 2007; King et al., 2007; Vandevoorde et
al., 2007). URB754 was thought to also be a selective MAGL inhibitor, although the initial
characterization of URB754 was recanted due to contaminant issues (Tarzia et al., 2007).
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However, the recent development of JZL184, a selective and efficacious MAGL inhibitor made
the task of assessing the contribution of MAGL inhibition possible. JZL184 elevates 2-AG
levels 8-10 fold but does not modulate levels of anandamide. Furthermore, JZL184 produced
analgesia in the tail-flick (Long et al., 2009a), as well as the chronic constriction injury model
(Kinsey et al., 2009a). Therefore, we tested the hypothesis that MAGL inhibition blocks acetic
acid induced abdominal stretching via a CB1 receptor mechanism. JZL184 dose-dependently
blocked acetic acid-induced abdominal stretching. This effect was mediated through the CB1
receptor.
We previously illustrated that FAAH and MAGL inhibition are capable of blocking
acetic acid abdominal stretching independent of each other. This information along with the fact
that FAAH is located in the postsynaptic terminal and MAGL is located presynaptically,
suggests that these lipids may activate different circuits in an effort to maintain homeostasis (on
demand synthesis and release). Due to the fact that inhibiting either endocannabinoid
degradative enzyme can suppress the nociceptive effect produced by acetic acid, we assessed the
effect of increasing both endocannabinoids simultaneously via dual inhibition of FAAH and
MAGL degradative enzymes. Using JZL184 in combination with FAAH (-/-) mice, or the dual
FAHH/MAGL inhibitor JZL195 significantly enhanced the suppression of abdominal stretches
in comparison to blocking one enzyme alone. Both effects were blocked by CB1 antagonism.
Although dual inhibition is seemingly beneficial from a therapeutic standpoint, studies from our
laboratory illustrated otherwise. Mice treated with the dual FAAH/MAGL enzyme inhibitor
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JZL195 (20 mg/kg) produced a greater antinociceptive response in the tail immersion assay of
thermal pain compared to FAAH or MAGL inhibitors alone. However, the same mice treated
with JZL195 also showed catalepsy and hypomotility which are characteristics of direct acting
cannabinoid agonist such as THC. Dual FAAH/MAGL inhibition also caused profound THClike discriminative stimulus effects as well in the discrimination model. The drug discrimination
model serves as an animal model for marijuana intoxication and drugs that substitute for THC in
this assay are predicted to have marijuana-like subjective effects in humans (Long et al., 2009b).
Therefore this study suggests that simultaneous elevation of anandamide and 2-AG produces
untoward psychoactive effects as those associated with direct acting cannabinoid agonist such as
THC. Further testing using isobolographic analysis could determine an ideal ratio of FAAH and
MAGL inhibitors given in combination that produce optimal antinociceptive effects, with
minimal side effects.
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Chapter 5:

FAAH inhibitors act in the nervous system to reverse lipopolysaccharide-

induced mechanical allodynia in mice

5.1 Development of the LPS-induced allodynia model
Inflammatory pain is a debilitating disease that can result in increase pain sensitivity. It
can be caused by various mediators such as neuropeptides and cytokines (interleukins: IL-1, IL2, IL-6, tumor necrosis factor alpha (TNF-α) which cannabinoids have been shown to modulate
(Cabral and Marciano-Cabral, 2005; Klein et al., 2003). Unlike the acetic acid abdominal
stretching model, cannabinoids in inflammatory pain models favor a CB2 receptor mechanism of
action (Ashton, 2007; Guindon and Hohmann, 2008; Gutierrez et al., 2007). Administration of
the selective CB2 agonist GW405833 produced anti-inflammatory effects in the carrageenan
model of inflammatory pain (Clayton et al., 2002). These effects were reversed with SR144528
suggesting a CB2 receptor involvement. Furthermore, it was demonstrated that exogenous 2-AG
administration produced antinociceptive effects in the formalin model of inflammatory pain
(Guindon et al., 2007). Inflammation was induced in rat hind paws by intraplantar injection of
formalin and subjects were assessed over the next 60 min. Exogenous 2-AG was administered
subcutaneously into the dorsal surface of the paw at doses 0.01-100 µg. 2-AG dose dependently
decreased pain behavior however these effects were blocked with the pretreatment of AM630, a
selective CB2 receptor antagonist and not AM251, a selective CB1 receptor antagonist.
Therefore, our aim in this chapter is to determine whether genetic deletion or pharmacological
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inhibition of the endocannabinoid catabolic enzyme FAAH and MAGL, block LPS-induced
allodynia. Additionally, we seek to determine if the anti-allodynic effects are mediated through
the CB1 or CB2 receptor.

5.2 Methods
Male C57BL/6 mice were injected intraplantarly in one paw with lipopolysaccharide
(LPS) and saline into the opposite paw. This model takes advantage of the fact that each mouse
serves as its own control, thereby eliminating the idea that motor deficits were the result of the
observed effect. LPS is a bacterial endotoxin derived from the outer cell wall of gram (-)
bacteria that induces an inflammatory response when injected into the paw. 24 h after mice are
injected with LPS they are examined for a tactile allodynic response. Allodynia is illustrated as a
painful response to a non-noxious stimuli, and can be assessed using von Frey filament hairs.
These filaments vary in thickness and possess different bending forces ranging from 0.6 g-6.0 g.
The bending force at which mice withdraw their paw is determined and recorded as the paw
withdrawal threshold (PWT).

Current models of inflammatory pain (e.g. carrageenan, complete freund’s adjuvant,
LPS) produce severe edema, which may confound interpreting of the results by decreasing the
observation of subtle behavioral effects, or by reducing the ability of mice to move their paw.
As a result we modified the previously characterized LPS model of inflammation developed out
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of our laboratory (Naidu et al., 2010), in order to induce tactile allodynia without producing overt
edema of the paw or eliciting a general malaise (e.g., loss of body weight). To ensure that our
model is representative for detecting analgesic compounds, we tested the positive control
gabapentin, which possesses efficacy in treating various types of pain (Staahl et al., 2009), and
served as the positive control. In addition, we examined the effects of global activation of
cannabinoid receptors, using the phytocannabinoid THC which was shown in the acetic acid
stretching model to have antinociceptive properties.
Intraplantar LPS elicited profound allodynia in the LPS-treated paw, but not the salinetreated, control paw [F(3,24)=10.54, p <0.001; Figure 17A], and occurred at concentrations 10
fold less than those required to produce paw edema [F(3,24)=11.18, p<0.0001; Figure 17B].
Whereas the high dose of LPS (25 µg) produced a significant increase in paw thickness, at 2.5
µg, LPS had no effect on edema measurements, as compared to the saline injected paw. In
addition to the lack of edematous actions caused by intraplantar injection of 2.5 µg LPS, no
weight loss occurred. Thus, this dose of LPS was used in all subsequent experiments.
LPS injection significantly decreased mechanical paw withdrawal threshold (PWT), as
compared to saline-treated paws, which remained constant throughout all of the studies. The
GABA analogue gabapentin significantly reversed LPS-induced allodynia [F(3,24)=4.4, p<0.05;
Figure 18A)]. Gabapentin did not affect paw withdrawal threshold in saline-injected control
paws (p=0.64; Figure 19A). Similarly, THC significantly reversed LPS-induced allodynia in the
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LPS-treated paw [F(3, 28)=5.71, p<0.01; Figure 18B], but did not modify the saline-treated paw
threshold (Figure 19B).

5.3 FAAH (-/-) mice show an anti-allodynic phenotype
In the second series of experiments, we examined whether genetic deletion of FAAH
reduces LPS-induced allodynia. FAAH-NS mice, which express the enzyme under a neural
specific enolase promoter (Cravatt et al., 2004), were used to distinguish whether inhibiting
FAAH expressed in the peripheral and/or nervous system(s) mediates the observed anti-allodynic
effects. Third, we examined whether pharmacological blockade of FAAH would reverse LPSinduced allodynia by comparing the anti-allodynic effects of the reversible, α-ketoheterocycle
FAAH inhibitor OL-135 (Boger et al., 2005; Lichtman et al., 2004), to two irreversible FAAH
inhibitors, the carbamate URB597 (Piomelli et al., 2006), and the piperidine urea PF-3845,
which carbamylates FAAH's serine nucleophile (Ahn et al., 2009).
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Figure 17. Intraplantar injection of LPS is more
potent in eliciting tactile allodynia than in
producing

paw

edema.

(A)

Decreased

mechanical paw withdrawal thresholds were
reduced in the LPS-injected paw 24 h after
injection. LPS injection, at doses of 2.5 µg or 25
µg per paw, increased sensitivity to tactile
stimulation that was significantly different from
paw withdrawal threshold in the saline injected
paw of the same mice.

(B) Paw edema was

significantly increased in hind paws injected
with the high dose of LPS (i.e., 25 µg). Control
paw represents the saline-injected paw of LPS treated mice. Values represent the mean (± SEM)
mechanical paw withdrawal threshold. n=6-9 mice/group. ** p < 0.01, ***p < 0.001 vs. salinetreated paw.
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Figure 18. Systemic administration
of gabapentin or THC reduces the
tactile allodynia caused by
intraplantar LPS (2.5 µg). (A)
Gabapentin (30 mg·kg-1) reversed
tactile allodynia induced by LPS. (B)
THC (5 or 10 mg·kg-1) reversed LPSinduced allodynia in the treated paw.
The control paw represents the salineinjected paw of LPS treated mice (C,
D). Values represent the mean (±
SEM) mechanical paw withdrawal
threshold. n=6-10 mice/group. * p <
0.05; ** p < 0.01 vs. vehicle in the
LPS-treated paw.
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Figure 19. Systemic administration of neither gabapentin (A) nor THC (B) affected paw
withdrawal thresholds in the control saline-injected paw. Values represent the mean (± SEM)
mechanical paw withdrawal threshold. Data from the LPS-treated paws are depicted in Figure
18. n=6-10 mice/group.
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FAAH (-/-) mice displayed significantly less allodynia to LPS treatment than either
FAAH (+/-) control mice or FAAH-NS mice [F(2,21)=8.99, p<0.01; Figure 20A]. FAAH-NS
mice showed wild type responses to LPS-induced inflammatory pain, indicating that the FAAH
anti-allodynic phenotype is mediated by elevated FAAs in the nervous system. In addition, there
were no genotype differences between groups in the saline-treated paw (p=0.96, Figure 21A).
Next, we examined the receptor mechanism(s) of action underlying the observed anti-allodynic
effects in FAAH-compromised mice. Several studies have implicated a role for CB1 receptors in
reducing hyperalgesia and CB2 receptors in ameliorating edema (see review (Anand et al., 2009).
A recent study from our laboratory illustrated that FAAH (-/-) mice showed an antiedematous
effect, which was prevented by pretreatment by the CB2 antagonist SR144528 and not the CB1
antagonist, rimonabant. However, the anti-hyperalgesic effects were blocked with both
rimonabant and SR144528 (Naidu et al., 2010). Furthermore, CB2 (-/-) mice were resistant to
the antiedmatous effects of FAAH inhibition suggesting a role for CB2 in modulating edema.
Another study demonstrated that in the carrageenan-evoked model of inflammation, the effects
of AM1241, a purported CB2 agonist, were blocked by SR144528, but not rimonabant
(Gutierrez et al., 2007)) again reinforcing the theory for CB2 receptor involvement in edema.
Conversely, the antihyperalgesic effects of cannabinoids are shown to be mediated through the
CB1 receptor mechanism of action. We showed in the previous chapters that phytocannabinoids
such as marijuana and FAAH inhibitors reduced acetic acid abdominal stretching, which was
reversed by rimonabant and not CB2 antagonism. Furthermore, other reports suggest a similar
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role for CB1 in modulating pain. Anandamide administered locally into the rat hind paw
reversed pain in the formalin pain model and was reversed by CB1 antagonism and not CB2
(Guindon et al., 2006; Gutierrez et al., 2007). Thus, we sought to determine whether these two
cannabinoid receptors play a role in the anti-allodynic effects of FAAH (-/-) mice in our model
of LPS-induced allodynia. To determine the receptor mechanism of action by which FAAH
inhibition caused anti-allodynic effects, FAAH (-/-) mice were pretreated with the CB1 receptor
antagonist, rimonabant or the CB2 receptor antagonist, SR144528. Either rimonabant or
SR144528 completely reversed the FAAH anti-allodynic phenotype (p<0.05; Figure 20B). No
significant effects were found in the saline-treated paw (Figure 21B).

5.4 Pharmacological blockade of FAAH reverses LPS-induced allodynia
Although genetic deletion of FAAH reversed the paw withdrawal thresholds,
pharmacological inhibition of FAAH is of clinical importance. Therefore, we examined whether
pharmacological blockade of FAAH would reverse LPS-induced allodynia by comparing the
anti-allodynic effects of the reversible, α-ketoheterocycle FAAH inhibitor OL-135 (Boger et al.,
2005; Lichtman et al., 2004), to two irreversible FAAH inhibitors, the carbamate URB597
(Piomelli et al., 2006), and the piperidine urea PF-3845, which carbamylates FAAH's serine
nucleophile (Ahn et al., 2009). In addition, LC/MS/MS analysis was used to quantify
endocannabinoid levels after systemic, local, and intracranial ventricular administration of PF3845. As shown in Figure 22A, administration of each FAAH inhibitor, PF-3845 [F(3,24)=6.07,
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p<0.01], URB597 [F(3,30)=5.95, p<0.01], or OL-135 [F(4,41)=3.82, p<0.01] significantly
reversed LPS-induced tactile allodynia, but did not modify paw withdrawal thresholds in the
saline-injected paw (Figure 23A). As shown in Table 7, i.p. administration of PF-3845 (10
mg·kg-1) led to significant increases of AEA levels, but not 2-AG levels, in the brain and spinal
cord. In light of the recent report of Clapper et al. (2010) showing that a peripherally restricted
FAAH inhibitor reduces pain responses, we next evaluated whether intraplantar administration of
PF-3845 reverses LPS-induced allodynia. Intraplantar administration of PF-3845 (1, 3, or 10 µg)
reversed allodynia in the LPS administered paw p<0.01 (Figure 22B), but did not affect
withdrawal responses in the saline-treated paw (Figure 23B). Additionally, local administration
produced a smaller effect when compared to systemic FAAH inhibition. More importantly, an
intraplantar injection of PF-3845 (1 µg) to the saline-treated paw did not alter allodynia in the
LPS-treated paw (Figure 22C), consistent with the notion that the drug effects were locally
mediated. The observation that intraplantar administration of PF-3845 at 1 µg did not affect
endocannabinoid levels in the brain or spinal cord, (see Table 7) further supports the idea that
these doses of PF-3845 were mediated through a local site of action.

86

Figure 20.

Deletion of FAAH

within the nervous system reduces
LPS-induced

allodynia.

(A)

Control FAAH (+/-) mice displayed
profound allodynic responses to
intraplantar LPS (2.5 µg), whereas
FAAH knockout mice (-/-) showed
an

anti-allodynic

phenotype.

FAAH-NS mice that express FAAH
exclusively
displayed

in
wild

response to LPS.

neuronal

tissue

type

allodynic

(B)

The anti-

allodynic phenotype in FAAH (-/-)
mice

was

pretreatment

suppressed
of

by

rimonabant

the
(3

mg·kg-1; Rim) and SR144528 (3 mg·kg-1; SR2). Control paw represents the saline-injected paw
of FAAH (+/-) LPS treated mice. All values represent the mean (± SEM) mechanical paw
withdrawal threshold. n=6-10 mice/group. ** p < 0.01 vs. FAAH (+/-) mice or FAAH-NS mice
(panel A);

##

p < 0.01 vs. LPS-treated FAAH (-/-) mice that received vehicle.
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Figure 21. (A) FAAH (-/-), FAAH-NS,
and FAAH (+/-) mice showed identical
paw withdrawal thresholds in the
control saline-injected paw. (B) FAAH
(-/-) and FAAH (+/-) mice displayed
similar withdrawal thresholds in the
control saline-injected paw and neither
rimonabant (3 mg·kg-1; Rim) nor
SR144528 (3 mg·kg-1; SR2) affected
control responses. All values represent
the mean (± SEM) mechanical paw
withdrawal threshold. Data from the
LPS-treated paws are depicted in
Figure 20. n=6-10 mice/group.
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In contrast, systemic administration of PF-3845 (10 mg/kg) or intraplantar injection of a much
higher dose of drug (i.e., 10 µg) caused significant increases in AEA, but not 2-AG levels in the
brain and spinal cord. However, no differences in paw skin endocannabinoid levels by PF-3845
were detected at the highest concentration tested (see Table 7). Furthermore, in order to
determine the location of FAAH inhibited anti-allodynic effects, we administered PF-3845
intrathecally. But first, we confirmed our method of injection by conducting a morphine dose
response study in the tail withdrawal assay. Intrathecal morphine dose responsively produced
antinociceptive response in the tail withdrawal model suggesting that our method of injection
was accurate and reproducible (Figure 24). Subsequently, we administered PF-3845 (1 µg -10
µg) in a total volume of 5 µl intrathecally then assessed mice for their paw withdrawal thresholds
following LPS. Mice treated with intrathecal PF-3845 showed a reversal of paw withdrawal
thresholds (Figure 25A). Conversely, the dose of PF-3845 that reversed paw withdrawal
thresholds also increased brain anandamide levels (Figure 25B) suggesting that drug spread
occurred. Due to the fact that intrathecal administration of low doses of PF-3845 resulted in
elevated levels of anandamide in the brain, we could not determine with certainty if FAAH
located spinally, or supraspinally in the case of intracranial administration mediated the antiallodynic effects seen in our previous studies with FAAH inhibition.
In order to determine if fatty acid amides were indeed producing the anti-allodynic effect
to FAAH inhibition, we examined whether PF-3845 would produce anti-allodynic effects in
FAAH-NS mice. As shown in Figure 26, PF-3845 (10 mg/kg) elicited significant anti-allodynic
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actions in FAAH (+/-) and FAAH (NS) mice, which significantly differed from mice treated with
LPS only [F(2,52)=4.35, p=0.018]. In contrast, PF-3845 did not alter the anti-allodynic
phenotype of FAAH (-/-) mice, suggesting that the anti-allodynic effects of this drug occurred
because of its inhibition of FAAH in the peripheral and/or central nervous system(s).
Additionally PF-3845 administration did not affect paw withdrawal in the control paw (Figure
27).
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Figure 22.

FAAH inhibitors reduce LPS-

induced allodynia. (A) Three different FAAH
inhibitors

dose-dependently

allodynia

24

administration.

h

after

reversed

tactile

intraplantar

URB597

(10

LPS

mg·kg-1;

downward triangle), PF-3845 (10 mg·kg-1;
circle),

and

OL-135

(30

mg·kg-1;square),

reversed the allodynic response produced by
intraplantar injection of LPS (2.5 µg).

Open

symbols represent the control-saline injected paw
of each respective treatment group.

(B)

Intraplantar administration of PF-3845 (1, 3, or
10 µg) partially reversed LPS-induced allodynia.
(C) PF-3845 administered to the saline-treated,
control paw did not reduce allodynic responses
in the LPS-treated paw. Control paw represents
the saline-injected paw of LPS only treated mice.
Values represent the mean (± SEM) mechanical paw withdrawal threshold. n=7-12 mice/group.
**p < 0.01 vs. vehicle treatment in the LPS-treated paw; ##p <0.01 vs. saline-treated paw.
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Figure 23. (A) Three different FAAH
inhibitors did not affect paw withdrawal
thresholds in the control saline-injected paw.
(B) Intraplantar administration of PF-3845
into the LPS-treated paw did not affect
withdrawal thresholds in the contralateral
saline-treated paw. (C) PF-3845 administered
to the saline-treated, control paw did not
affect withdrawal responses. Values represent
the

mean

(±

SEM)

mechanical

paw

withdrawal threshold. Data from the LPStreated paws are depicted in Figure 22. n=712 mice/group.
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Figure 24. Morphine produces antinociception in the tail withdrawal assay. Intrathecal
morphine (0.1 µg-10 µg) dose-responsively produces antinociception in the tail withdrawal assay
of thermal nociception. Data represents the mean ± SEM tail withdrawal latency. p < 0.01 vs
saline. n=6 mice per group.
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Figure 25. Spinal PF-3845 produces antinociception. Intrathecal PF-3845 (3 µg) reverses LPSinduced allodynia (A) and increases brain anandamide (AEA) levels versus vehicle (B). Data
represents the mean (± SEM) mechanical paw withdrawal. Values in panel B are calculated per
wet tissue weight. n=6 mice per group. Data represent the mean (± SEM) endocannabinoid
content the **p<0.01 vs control. n=6-10 mice/group

A

B
AEA (pm/g)

2-AG (nm/g)

Vehicle

4.91 ± .97

7.78 ± .76

PF-3845 (3ug)

30.85 ± 2.01**

6.97 ± 1.01
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Table 7. LC/MS/MS analysis of brain and spinal cord tissues after systemic (10 mg/kg; i.p.) or
local (0.1-10 µg; intraplantar) PF-3845 administration in mice. Systemic administration of PF3845 significantly increased anandamide (AEA) levels in both brain and spinal cord p<0.001.
Local administration of PF-3845 (10 µg), but not 0.1 or 1.0 µg, increased AEA in the brain and
spinal cord tissues. “ND: not determined”. Values are calculated per wet tissue weight. n=6
mice per group. Data represent the mean (± SEM) endocannabinoid content.

Brain
Administration

Spinal Cord

Paw Tissue

Injection

AEA (pm/g)

2-AG (nm/g)

AEA (pm/g)

2-AG (nm/g)

AEA (pm/g)

2-AG (nm/g)

i.p.

Vehicle

1.55 ± 0.11

9.04 ± 0.89

3.95 ± 0.18

9.35 ± 1.23

ND

ND

i.p.

PF-3845

16.67 ± 1.15**

9.80 ± 1.02

37.78 ± 2.15**

10.32 ± 2.22

ND

ND

route

(10 mg/kg)

Intraplantar

Vehicle

4.32 ± 0.84

6.82 ± 0.74

5.34 ± 0.60

10.34 ± 0.61

6.14 ± 0.50

2.47 ± 0.23

Intraplantar

PF-3845

5.55 ± 0.62

7.42 ± 0.42

6.88 ± 1.14

12.41 ± 0.79

ND

ND

5.69 ± 0.81

7.00 ± 0.38

6.50 ± 0.54

11.84 ± 0.77

ND

13.12 ± 0.40**

5.56 ± 0.58

28.42 ± 1.85**

7.34 ± 0.74

6.61 ± 0.41

(0.1 µg)
Intraplantar

PF-3845

ND

(1.0 µg)
Intraplantar

PF-3845
(10.0 µg)
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2.48 ± 0.07

Figure 26. Blocking FAAH in the nervous system mediates the FAAH (-/-) anti-allodynic
phenotypic in response to intraplantar LPS.

FAAH (-/-) mice displayed an anti-allodynic

phenotype that was not present in either the FAAH (+/-) mice or FAAH-NS (i.e., neural specific
knock-in) mice. Pretreatment with PF-3845 (10 mg/kg) restored the anti-allodynic phenotype in
FAAH (+/-) mice and FAAH-NS mice. Control paw represents the saline-injected paw of
FAAH (+/-) LPS only treated mice. All values represent the mean (± SEM) mechanical paw
withdrawal threshold. n=8-10 mice/group. **p < 0.01 vs. the vehicle-treated FAAH (+/-) or
FAAH-NS mice, #p <0.05, ##p < 0.01 vs. vehicle-treated mice for each respective genotype.
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Figure 27. PF-3845 (10 mg/kg; i.p.) did not affect paw withdrawal thresholds in the control
saline-injected paw. All values represent the mean (± SEM) mechanical paw withdrawal
threshold. Data from the LPS-treated paws are depicted in Figure 26. n=8-10 mice/group.
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5.5 CB1 and CB2 receptors mediate the anti-allodynic effect of FAAH inhibition
FAAH (-/-) mice and wild type mice treated with FAAH inhibitors display an antiallodynic effect when administered LPS. These effects were completely reversed with either a
CB1or CB2 receptor selective antagonist. Consequently, we evaluated the effects of PF-3845 in
a complementary approach using CB1, and CB2, receptor knockout mice. CB1 (-/-) and CB2 (-/) mice as well as their matched littermates, were administered LPS intraplanatarly into one paw
and saline into the opposite paw. Twenty-two hrs later PF-3845 (10 mg/kg; i.p) or vehicle was
administered and allodynia testing was conducted 2 hrs later. PF-3845 increased the paw
withdrawal threshold values in CB1 (+/+) mice as well as in CB2 (+/+) mice (p<0.01 for each)
after LPS administration, but failed to increase paw withdrawal thresholds in either CB1 (-/-)
mice (Figure 28A) or CB2 (-/-) mice (Figure 28B). As found previously, PF-3845 administration
did not modify paw withdrawal threshold responses to the saline-treated paw (Figure 29A, B).
Since anandamide and other ligands that are targets of FAAH bind to and activate other
receptors such as the TRPV1 ion channel, PPAR-α receptors, we evaluated these receptor
systems which may also contribute to the anti-allodynic actions of PF-3845. AEA was shown to
act as a full agonist at the human vanilloid receptor (Smart et al., 2000). In addition to FAAHs
regulation of AEA, FAAH also controls the degradation of non-cannabinoid fatty acid amides,
such as N-palmitoyl ethanolamine (PEA) and OEA, each of which possesses anti-inflammatory
actions through the PPAR-α receptor (Jhaveri et al., 2008;. D’Agostino et al., 2007). Lastly,
naloxone has been shown to reduce the antinociceptive actions of the FAAH inhibitor OL-135
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(Chang et al., 2006). Thus, we explored whether these non-cannabinoid receptors also play a
role in the anti-allodynic effects of PF-3845.
C57BL/6 mice were injected with LPS into one paw and saline into the opposite paw as
previously mentioned. 22hrs after LPS administration mice were pretreated subcutaneously with
either the opioid receptor antagonist naltrexone (1 mg/kg), the TRPV1 antagonist IRTX (0.5
mg/kg), or the PPAR-α antagonist MK886 (3 mg/kg). Ten minutes after the administration of
selective receptor antagonists, mice were injected with PF-3845 (10 mg/kg) and assessed for
allodynia after 2 hrs. None of the antagonists modified the anti-allodynic effects of PF-3845
(Figure 28C) and had no effects on LPS-induced allodynia when given alone (Figure 30). As
before, no effects of drug treatment were observed on the control paw (Figure 29C).
In opposition to FAAH inhibition which produces anti-allodynic effects we found that
MAGL inhibition is ineffective. Following the same model for LPS-induced allodynia, we
pretreated mice with JZL184 (40 mg/kg), the selective MAGL inhibitor 2 h prior to testing for
allodynia. JZL184 treated mice did not show an anti-allodynic response as demonstrated with
mice treated with PF-3845 (Figure 31). However, these mice did show increased hyperreflexia
at the dose tested.
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Figure 28. PF-3845 reduces LPS-induced allodynia
through a cannabinoid receptor mechanism of action.
(A) PF-3845 (10 mg/kg) reduced LPS-induced
allodynia in CB1 (+/+) mice, but not in CB1 (-/-)
mice. Control paw represents the saline-injected paw
of CB1 (+/+) LPS only treated mice. (B) PF-3845
(10 mg/kg) reduced LPS-induced allodynia in CB2
(+/+) mice, but not in CB2 (-/-) mice. Control paw
represents the saline-injected paw of CB2 (+/+) LPS
only treated mice. (C) The anti-allodynic effects of
PF-3845 (10 mg/kg) in the LPS model were not
blocked by the opioid receptor antagonist naltrexone
(1 mg/kg), the TRPV1 receptor antagonist IRTX (0.5
mg/kg), or the PPAR-α antagonist MK886 (3
mg/kg). Data shown in Panel C represent two
combined experiments collapsed into a single figure.
Control paw represents the saline-injected paw of
LPS only treated mice. n=6-10 mice/group. Values represent the mean (± SEM) mechanical
paw withdrawal threshold. **p < 0.01 vs. Vehicle-treated mice in the LPS-injected paw; ##p <
0.01 vs. PF-3845-treated CB1 (+/+) or CB2 (+/+) mice.
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Figure 29. (A) CB1 (+/+) and (-/-) mice show
similar paw withdrawal thresholds in the control
saline-injected paw and PF-3845 (10 mg/kg; i.p.)
had no effects in either genotype. (B) CB2 (+/+) and
(-/-) mice show similar paw withdrawal thresholds in
the control saline-injected paw and PF-3845 (10
mg/kg; i.p.) had no effects in either genotype. (C)
None of the drug treatments from Figure 28 affected
paw withdrawal thresholds in the control salineinjected paw. Values represent the mean (± SEM)
mechanical paw withdrawal threshold. n=6-10
mice/group.
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Figure 30. None of the antagonists administered in the absence of a FAAH inhibitor affected
tactile paw withdrawal thresholds in either allodynic LPS-injected paws or control salineinjected paws. Values represent the mean (± SEM) mechanical paw withdrawal thresholds in
LPS- and saline-treated paws. Rimonabant (Rim; 3 mg/kg), SR144528 (SR2; 3 mg/kg),
naltrexone (Nal; 1 mg/kg), MK886 (MK; 3 mg/kg), and IRTX (0.5 mg/kg). n=6-14 mice/group.
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Figure 31. MAGL inhibition in LPS-induced allodynia model. JZL184 (40 mg/kg) failed to
produce antinociception in the LPS-induced allodynia model. Values represent the mean (±
SEM) mechanical paw withdrawal threshold. n=6-8 mice/group
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5.6 Discussion: FAAH inhibition reverses LPS induced allodynia via CB1 and CB2 receptors
Allodynia and hyperalgesia are common clinical features of many inflammatory diseases
and disorders such as fibromyalgia, postherpetic neuralgia, and mild skin injuries. Whereas
hyperalgesia reflects an increased sensitivity to a noxious stimulus, allodynia is a painful
response to a typically non-noxious stimulus. In a murine model of inflammatory pain, LPS
injected into the hind paw leads to increased sensitivity to thermal nociceptive stimuli (Kanaan et
al., 1996; Naidu et al., 2010). In the present chapter, we modified the previously established LPS
model (Naidu et al., 2010) by injecting a relatively low concentration of LPS (2.5 µg) into the
plantar surface of a hind paw to elicit a profound tactile allodynic response at 24 h, without
producing overt edema or weight loss. A previous report from our laboratory showed maximum
thermal hyperalgesic responses to 25 µg/paw LPS, though mice in that study also displayed
severe edematous effects of the paw and significant weight loss, indicating systemic effects of
LPS (Naidu et al., 2010). Gabapentin, a commonly used anti-allodynic GABA analogue, as well
as the phytocannabinoid THC, reversed LPS-induced allodynia. However, each of these drugs
produces significant motor and cognitive side effects (Backonja et al., 1998; Martin et al.,
1991a). In contrast, elevating the endocannabinoid AEA, by blocking its catabolic enzyme
FAAH, is well established to reduce nociceptive behavior in a variety of animal models of pain,
without eliciting cannabimimetic side effects associated with THC. Therefore, we investigated
whether genetic deletion or pharmacological inhibition of FAAH, the primary catabolic enzyme
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of AEA, would reduce LPS-induced allodynia. Both approaches reduced tactile allodynia via
mechanism(s) that required both CB1 and CB2 receptors.
FAAH (-/-) mice displayed a significant anti-allodynic phenotype. However, it is
difficult to delineate whether the anti-allodynic responses of FAAH (-/-) mice resulted from
increased levels of AEA and other FAAs at the time of testing or because the development of the
LPS-induced allodynia was dampened. However, an acute injection of three different FAAH
inhibitors reversed the peak allodynic effects of LPS. The reversible (OL-135) and irreversible
(URB597, PF-3845) FAAH inhibitors attenuated LPS-induced allodynia. URB597 has antihyperalgesic effects in various models of inflammatory pain, such as carrageenan and complete
Freund’s adjuvant (CFA) models (Holt et al., 2005; Jayamanne et al., 2006). Similarly, the
reversible FAAH inhibitor, OL-135 suppressed nociception in thermal pain models (i.e. tail
immersion, hot-plate) and the formalin model of pain (Lichtman et al., 2004). Here, we show for
the first time OL-135 elicits anti-allodynic effects in an inflammatory pain model. Likewise, PF3845, which has longer lasting effects than other FAAH inhibitors, also reduced allodynia in the
rat CFA model (Ahn et al., 2009).
These results further demonstrate both CB1 and CB2 receptors play a necessary role in
mediating the anti-allodynic phenotype of FAAH-compromised mice in the LPS model. These
data are congruent with other reports showing both CB1 and CB2 receptors are required for the
anti-allodynic effects of FAAH inhibition, such as the chronic constriction injury model (Kinsey
et al., 2009a; Kinsey et al., 2010; Russo et al., 2007) and the partial sciatic and spinal nerve
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injury models of pain (Desroches et al., 2008; Jhaveri et al., 2006). The resultant may be
attributed to the sequestration of the cannabinoid receptors. In situ hybridization revealed that
CB1 receptors are expressed in cells of the dorsal root ganglia inserted on nerve terminals in the
periphery and other brain regions associated with pain such as the PAG (Hohmann and
Herkenham, 1999). Furthermore, the CB2 receptor is expressed on activated mast cells (Facci et
al., 1995) which infiltrate peripheral nerve tissues during an innate inflammatory response, such
as that initiated by LPS exposure. However, the two cannabinoid receptors play differential roles
in mediating the antinociceptive actions of FAAH blockade in other pain models. Only the CB1
receptor mediates the antinociceptive effects of FAAH (-/-) mice in the tail withdrawal and
formalin test (Lichtman et al., 2004). In contrast to the data in the present study demonstrating
FAAH inhibitors require both cannabinoid receptors to reduce tactile allodynia caused by LPS,
we previously reported FAAH inhibition ameliorates thermal hyperalgesia through the activation
of CB1 receptors, only (Naidu et al., 2010). The phenotypic anti-edematous actions caused by
FAAH deletion are mediated by the CB2 receptor, not the CB1 receptor, in carrageenan
(Lichtman et al., 2004) and LPS (Naidu et al., 2010) paw inflammatory assays.
FAAH-NS mice, which express FAAH in the nervous system only (Cravatt et al., 2004),
displayed the same allodynic responses to intraplantar LPS as wild type controls. This finding
along with the observation that the highly selective FAAH inhibitor, PF-3845, produced antiallodynic effects in FAAH-NS mice supports the idea that the anti-allodynic effects of FAAH
inhibition are mediated in the central and/or peripheral nervous system(s). In contrast, we
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recently reported that FAAH-NS mice show an anti-edematous phenotype when given an
intraplantar injection of 25 µg LPS (Naidu et al., 2010). The results of these studies indicate that
different pools of FAAs mediate the edematous vs. allodynic effects of LPS. Whereas elevating
these lipid signaling molecules in non-neuronal tissue mediates the anti-edematous effects, the
anti-allodynic actions appear to be mediated through the nervous system. Of note, a recent study
found that a peripherally restricted FAAH inhibitor (URB937) reduced mechanical and thermal
hyperalgesia in the carrageenan inflammatory pain model as well as the peripheral nerve injury
pain model (Clapper et al., 2010). Thus, targeting FAAH in the peripheral nervous system, as
well as in the central nervous system (Suplita et al., 2005), effectively blocks pain-related
behavior, possibly by differentially elevating distinct pools of FAAs. In agreement with
previous data, systemic administration of PF-3845 increased AEA levels in the brain (Ahn et al.,
2009) and spinal cord without increasing levels of 2-AG. Furthermore, we found local
administration of PF-3845 into the LPS-injected paw reduces the tactile allodynic response to
LPS without affecting levels of AEA in the brain or spinal cord, indicating that the anti-allodynic
effects of PF-3845 were not merely due to diffusion into the CNS. That said, the lack of
increased levels of AEA in paw skin by PF-3845 may be limited by challenges associated with
extracting lipids from mouse skin or possibly low levels of FAAH on discrete sensory neurons
relative to the large surface area of the paw. Regardless, the observation that local PF-3845
administration yielded small magnitude, anti-allodynic actions compared to systemic
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administration suggests that central as well as peripheral components contribute to maximal antiallodynic efficacy of FAAH inhibitors.
The endotoxin model used in the present study differs from other models of
inflammation, in that LPS is derived from the outer cell wall of gram negative bacteria and is
commonly used to model an innate inflammatory response. Unlike the carrageenan model and
complete Freund’s adjuvant model, there is not severe weight loss or measurable changes in paw
edema. Similar to other inflammatory pain models, such as injection of CFA (derived from a
mycobacteria) or carrageenan (extracted from red seaweed), LPS mimics an inflammatory
response to a non-self immunogen which produces an allodynic response.
The finding that PF-3845 was ineffective in CB1 (-/-) and CB2 (-/-) mice confirms the
essential role of both the CB1 and CB2 receptors in mediating LPS-induced allodynia. CB2
receptors are highly expressed on immune cells and may play an essential role in modulating the
release of inflammatory cytokines/chemokines involved in pain sensitization (Klein et al., 2003;
Roche et al., 2006). Therefore, changes in the inflammatory pain response may be attributed to
the activation of the CB2 receptors, which alternatively decrease the release of cytokines and the
resulting allodynia. Although the CB2 receptor is expressed at low levels in the nervous system
and much higher levels on mast cells (Facci et al., 1995), previous evidence suggests that it is
upregulated in the dorsal horn in neuropathic pain models (Beltramo et al., 2006; Hsieh et al.,
2011), hence changes in CB2 expression during a disease state may be responsible for the strong
role of CB2 in modulating LPS-induced allodynia. Furthermore, a recent report by Hsieh et al.,
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(2011) also illustrated that in the CFA model of inflammation, CB2 receptor mRNA, but not CB1
receptor mRNA, is up-regulated in the dorsal root ganglia and paw tissue, but not in the spinal
cord. Conversely, the CB1 receptor is expressed at much higher levels in the nervous system
than in other tissues (e.g., immune cells) and has a more prominent role in modulating
neurotransmitter signaling than the CB2 receptor. However, due to the limitations of the test
(e.g. floor effect) it is difficult to determine whether genetic deletion of CB2, for example, would
exacerbate LPS-induced allodynia. Notably, local administration of low doses of PF-3845
partially reversed allodynia, suggesting FAAH in the peripheral nervous system modulates
inflammatory pain in the LPS-induced allodynia model.
A growing body of research suggests non-cannabinoid receptors play a role in the antiinflammatory actions of FAAH inhibitors (Chang et al., 2006; Sun et al., 2006; Tognetto et al.,
2001). Although AEA is an agonist at the cannabinoid receptor, it also activates the TRPV1
receptor; albeit its affinity at TRPV1 is lower than its affinity at cannabinoid receptors (Howlett
et al., 2002; Zygmunt et al., 1999). The TRPV1 receptor has also been implicated in AEA
effects in other models of pain to include the carrageenan-induced thermal hyperalgesia model,
and the Hargreaves plantar stimulator test (Horvath et al., 2008; Maione et al., 2006). However,
we show that in the LPS-induced inflammatory pain model, the TRPV1 antagonist, IRTX failed
to block the anti-allodynic effects of PF-3845. In addition to increasing systemic AEA, FAAH
inhibition also increases levels of noncannabinoid FAAs, such as oleoylethanolamide (OEA),
oleamide, and palmitoylethanolamine (PEA) (Clement et al., 2003). In particular, the PPAR-α
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receptor has been implicated in anti-inflammatory effects of OEA and PEA (Jhaveri et al., 2008).
Moreover, PEA attenuates inflammation in the carrageenan paw edema (D'Agostino et al., 2009)
and phorbol ester ear edema models (LoVerme et al., 2005), and PPAR-α (-/-) mice are
unaffected by exogenous administration of PEA (Lo Verme et al., 2005). To assess whether
targets of these other FAAH substrates contribute to the anti-allodynic effects of PF-3845, we
tested whether the anti-allodynic effect of FAAH inhibition was mediated through the PPAR-α
receptor. The PPAR-α antagonist MK886 did not block the anti-allodynic effects of FAAH
inhibition, indicating PPAR-α does not play a necessary role in the anti-allodynic effects of PF3845.

Lastly, it was reported that naloxone reversed analgesia induced by a FAAH inhibitor,

OL-135 in the mild thermal injury and spinal nerve injury rat pain models (Chang et al., 2006).
Here, we found no evidence of the opioid receptor involvement in the anti-allodynic effects of
PF-3845. Additionally, these data support previous work from our laboratory negating the role
of opioid receptor involvement with FAAH inhibition in mouse peripheral nerve injury (Kinsey
et al., 2009) and visceral pain models (Kinsey et al., 2009b; Naidu et al., 2009).
Inhibiting MAGL did not produce the anti-allodynic response that FAAH inhibition
produced. The highest dose of MAGL inhibitor tested (JZL184; 40 mg/kg) was illustrated to
produce analgesia in a variety of pain models such as the tail-flick assay, acetic acid abdominal
stretching, and chronic constriction injury models (Kinsey et al., 2010; Long et al., 2009a).
However, the lack of effect in the LPS model may be due to the fact that MAGL inhibition at the
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concentration tested also produced hyperreflexia which is similar to previous studies (Long et al.,
2009a).
In summary, these results indicate that genetic deletion or pharmacological inhibition of
FAAH reduces LPS-induced pain responses. In particular, we demonstrated that three distinct
FAAH inhibitors reverse LPS-induced tactile allodynia. Furthermore, these data reveal that
neuronal FAAH inhibition is primarily responsible for the anti-allodynic response to LPS via a
mechanism requiring both cannabinoid receptors.
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Chapter 6: General Conclusions and Discussion
The overall purpose of this dissertation was to examine the effects of targeting the
endocannabinoid system on visceral and inflammatory pain states. We generated two
hypotheses to address our purpose. First, we hypothesized that prevalent phytocannabinoids
reduce acetic acid induced abdominal stretching via a CB1 receptor mechanism of action.
Secondly, we hypothesized that targeting the endocannabinoid system directly by using selective
cannabinoid agonist, or indirectly by elevating endocannabinoids via inhibiting their degradative
enzymes (i.e. FAAH and MAGL) reduce visceral and inflammatory pain.

6.1 Phytocannabinoids reduce visceral pain
To address the hypothesis that phytocannabinoids reduce visceral pain through a CB1
receptor mechanism of action, we carried out a series of pharmacological experiments. Utilizing
the five most prevalent cannabinoid constituents found in marijuana (Elsohly and Slade, 2005)
we showed that although these prevalent phytocannabinoids are structurally similar to THC, they
show different pharmacological properties in modulating visceral pain. For example, THC,
THCV, and CBN all showed affinity for the cannabinoid receptor. THC and THCV binding
affinities were 3 times greater than that of CBN. Consequently, they were all effective at
modulating CB1 mediated effects. THC and CBN reduced the total number of abdominal
stretches over the test period, although THC was approximately 50 times more potent than CBN.
Additionally, THC was more potent in blocking stretching than in producing motor impairment.
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CBC and CBD showed low affinity for the cannabinoid receptor and as a result did not affect
abdominal stretching. In an effort to determined if these effects were mediated through CB1 or
CB2 receptors we employed selective antagonists for each (rimonabant and SR144528
respectively). Both THC and CBN antinociceptive effects were blocked by the administration of
rimonabant but not SR2, proving that this was a CB1 driven effect. Conversely, the
concentration of THC and CBN that reduced abdominal stretching was not a result of motor
deficits. The concentration of THC needed to suppress motor deficits was 8 fold greater than
that dose which was antinociceptive.
Interestingly, we showed that THCV antagonized the effects of THC. THCV has been
shown to have both agonist and antagonist properties at the CB1 receptor as a function of dose.
Bolognini and colleagues showed that THCV reduced formalin nociceptive behavior at moderate
doses up to 5 mg/kg via a CB1 and CB2 mechanism of action (Bolognini et al., 2010). On the
other hand, data from other groups show that THCV was able to antagonize the effects of THC
in the tetrad when administered intravenously at doses up to 3 mg/kg (Pertwee et al., 2007). The
observation that THCV possesses both agonist and antagonist effects may be linked to the fact
that it is targeting non-specific targets at high doses, or concentrations such as PPAR receptors or
TRP channels (De Petrocellis et al., 2010). More recent studies showed that heterogeneous
mixtures of certain phytocannabinoids interact with each other to modulate the overall effect of
THC. A recent study from our laboratory showed that a high dose of CBC can augment the
pharmacological effects of a threshold dose of THC (DeLong et al., 2010). Another example of
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THC modulation by other phytocannabinoids is in the case of a new clinical drug, Sativex (GW
Pharmaceuticals, 2003). Sativex was recently developed by GW pharmaceuticals as an oral
delivery cannabinoid spray for the treatment of multiple sclerosis which has been approved in the
United Kingdom. The oral spray is formulated in a 1:1 mixture of THC and CBD. Although
CBD is ineffective on its own in reducing analgesia, it can modulate the effects of THC.
Although this mechanism of potentiation is unknown, CBD may interfere with the
pharmacodynamic properties of THC rather than pharmacokinetic interactions (Karschner et al.,
2011). Studies from our lab showed that high doses of intravenously administered CBD
potentiated the antinociceptive effects of a threshold dose of THC in the tail-flick assay
compared to CBD alone. Also, THC levels in the brain and blood of mice pretreated with CBD
were significantly higher than mice that only received THC suggesting that CBD may block the
degradation of THC (Varvel et al., 2006). Additionally, other studies suggest that this non
psychoactive compound CBD, can antagonize the reuptake of anandamide in in vitro studies
(Rakhshan et al., 2000). However, these effects only occurred at high micromolar concentrations
which may not be as relevant for in vivo studies.
These data strongly suggest that phytocannabinoids and other components that are found
in marijuana have a widespread effect on the physiological function of multiple systems and their
interaction with each other may contribute to the overall pharmacological effects of cannabis
sativa.
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6.2 Targeting the endocannabinoid system blocks visceral pain
The data presented in this thesis supports the hypothesis that the endocannabinoid system
serves as a target for treating visceral pain. THC is a mixed CB1/CB2 agonist therefore the goal
of these experiments was to evaluate selective agonist for each subtype. We employed selective
CB1 (ACEA) and selective CB2 (O-3223) agonists to determine if stimulating each respective
receptor would reduce abdominal stretching. ACEA but not O-3223 reduced nociceptive
responses in the acetic acid abdominal stretching model. Furthermore, the effects of ACEA were
blocked with pretreatment of rimonabant, confirming a CB1 receptor mediated mechanism.
We further investigated the antinociceptive effects of inhibiting degradative enzymes
FAAH and MAGL in the acetic acid stretching model. Initially, we took a genetic approach
looking at the effects of FAAH deletion using FAAH (-/-) mice. FAAH (-/-) mice displayed an
antinociceptive phenotype as compared to their wild type FAAH (+/+) littermates. This effect
was blocked in FAAH (-/-) mice treated with rimonabant, suggesting a CB1 mechanism of
action. A more relevant approach and of most importance clinically is whether pharmacological
agents can also produce a similar analgesic effect. Therefore, we assessed the effects of
irreversible and reversible pharmacological inhibitors of FAAH. Reversible inhibitors in general
are clinically important since they do not change the functional aspects of the enzyme like
irreversible inhibitors. This is important clinically because reversible inhibitors can be overcome
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with the addition of more substrates in the case of an overdose. URB597 the irreversible
inhibitor, and OL-135 the reversible inhibitor both reduced abdominal stretches compared to
vehicle administration although the dose of URB597 was 3 times more potent than that of OL135. The antinociceptive effects of both inhibitors were reversed by rimonabant and not the CB2
receptor antagonist. Furthermore we showed that non cannabinoid receptors such as the opioid
receptors did not have a factor in modulating these effects. This is a relevant issue with the use
of certain drugs in that they tend to reduce nociception, but they also have a non-specific
receptor mechanism. A report by Chang et al., 2006 showed that the effects of OL-135 was
reversed by naloxone in the spinal nerve ligation (SNL) and mild thermal injury (MTI) models.
However, the results from studies in our laboratory do not support the involvement of mu opioid
receptors in the antinociceptive effects of FAAH inhibitors in the chronic constriction injury
model (Kinsey et al., 2009a; Kinsey et al., 2010), in the acetic acid induced abdominal stretching
model, (Naidu et al., 2009), and the LPS-induced inflammatory model (see Figure 28C). The
differences may be due in part that Chang et al., (2006) used rats for their test subjects, where as
we used mice. Our data indicate that FAAH blockade can reduce nociception, although this
effect was below a 50% reduction, therefore we investigated the effects of dual FAAH and COX
inhibition on acetic acid abdominal stretching. Isobolographic analysis revealed that dual
FAAH/COX inhibition produces synergism in blocking the stretching response, an effect of
therapeutic importance. Drug combination therapy is beneficial in that it can reduce the
unpleasant side effects of certain drugs while at the same time maintain its therapeutic effects.
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Although FAAH inhibited effects have been characterized in several assays to treat pain
and inflammation (Schlosburg et al., 2009b) limited data is known about MAGL inhibited
effects. This is mostly in part due to the lack of selective MAGL inhibitors available. However,
the recent development of JZL184 was described to be highly selective for MAGL (Long et al.,
2009a). We showed for the first time behaviorally that MAGL inhibition via JZL184
administration reduced antinociceptive responses via CB1 receptor mechanism of action. Given
that FAAH and MAGL regulate different enzymes, and inhibiting either enzyme produces
antinociceptive properties, we evaluated the effects dual FAAH and MAGL inhibition. It is
possible that elevating both endocannabinoids can potentiate the antinociceptive effects of
elevating one. Conversely, elevating one endocannabinoid may suffice to block nociception
since both FAAH and MAGL inhibited effects are mediated through the CB1 receptor. To
address this idea we employed the use of FAAH (-/-) mice treated with JZL184, and the dual
FAAH/MAGL enzyme inhibitor. We demonstrated that by blocking MAGL and FAAH via the
dual inhibitor JZL195, or FAAH (-/-) mice treated with JZL184, the antinociceptive effects in the
abdominal stretching model are potentiated versus inhibiting one enzyme alone. These effects
were also mediated through the CB1 receptor mechanism of action. However it was also
discovered in a parallel study from our collaborators that dual elevation of AEA and 2-AG
resulted in cannabimimetic effects in THC drug discrimination studies (Long et al., 2009). The
drug discrimination model serves as an animal model for marijuana intoxication and drugs that
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substitute for THC in this assay are predicted to have marijuana-like subjective effects in humans
(Long et al., 2009b). Therefore this study suggests that simultaneous elevation of anandamide
and 2-AG produces untoward psychoactive effects as those associated with direct acting
cannabinoid agonist such as THC. Conversely, inhibiting one enzyme alone did not produce
THC-like effects. These data suggest that activation of the CB1 receptor by AEA and 2-AG are
potentiated indicative of endocannabinoid crosstalk.

6.3 Targeting the endocannabinoid system blocks inflammatory pain
As a final goal of this dissertation, we tested whether inhibition of FAAH and MAGL
produces an anti-allodynic effect in an inflammatory pain model, and if so, through which
receptor mechanism of action. To assess this question we modified an inflammatory model of
LPS-induced allodynia that produces increase responsiveness to non-noxious stimuli but does
not produce edema, or weight loss. The positive control gabapentin and primary
phytocannabinoid THC were capable of reversing paw withdrawal thresholds, which ensured us
that our model was capable of detecting drugs that had anti-allodynic properties. After
establishing an inflammatory pain model, we tested whether genetically modified FAAH mice
would display an anti-allodynic phenotype in this model. To address this question we employed
FAAH (-/-) mice as well as FAAH-neurospecific (FAAH-NS) mice. FAAH-NS mice were
generated by coupling the FAAH enzyme to the neuro-enolase promoter and mating them with
FAAH (-/-) mice. Subsequently, FAAH is only expressed in neuronal tissue (Cravatt et al.,
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2004). This creation is effective in deciphering whether FAAH inhibited effects are mediated
through the nervous system or in the periphery. FAAH (-/-) mice but not FAAH-NS displayed
an anti-allodynic phenotype, which was mediated through the CB1 and CB2 receptor mechanism
of action.
In parallel to the anti-allodynic effects with genetic deletion of FAAHs in the LPS model,
we also evaluated the effects of pharmacological inhibition of FAAH using reversible and
irreversible inhibitors. URB597, PF-3845, and OL-135 all reversed LPS-induced allodynia,
although the reversible inhibitor (OL-135) required a higher dose. In addition, we demonstrated
that these effects were abolished in CB1 (-/-) and CB2 (-/-) mice. To determine if FAAs were
indeed mediating the anti-allodynic effects observed in FAAH (-/-) mice administered LPS, we
pretreated FAAH-NS mice with PF-3845. PF-3845 restored the anti-allodynic phenotype in
FAAH-NS mice and did not affect FAAH (-/-) mice suggesting that inhibition of FAAH within
the nervous system (central and/or peripheral) elicits the anti-allodynic effects in this model.
Since inhibition of neuronal FAAH was mediating the anti-allodynic response, we
attempted to elucidate the precise location (e.g. central or peripheral) for its effects. To examine
this objective, we took several steps. First, we administered the selective FAAH inhibitor PF38845 via local, spinal, and supraspinal routes of administration. Local administration of PF3845 dose responsively reversed paw withdrawal thresholds and was mediated through both CB1
and CB2 receptor mechanism of action. Furthermore, the lowest dose that reversed allodynia
when administered to the contralateral saline injected paw and not the LPS treated paw did not
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affect the paw withdrawal threshold in the LPS paw suggesting that drug spread did not occur.
Since FAAH inhibition elevates AEA we wanted to confirm our local site of action, thus we
assessed whether local administration of PF-3845 increased levels of anandamide in the brain,
spinal cord, and paw. The highest dose tested (10 µg) increased anandamide in both the brain
and spinal cord, but not in the paw indicating that drug spread was occurring at this higher dose.
Conversely, local administration of the lower dose of PF-3845 (1 µg) did not affect brain and
spinal cord anandamide levels. Although no changes in paw tissue were quantified even at the
highest dose, we cannot draw conclusions about this effect. Possible explanations may be linked
to the fact that the larger surface area of the paw can dilute the changes in local anandamide
levels. An alternative approach in the future would be to look at specific areas of the paw
instead of assessing the whole paw. Another explanation is that changes in anandamide after
local administration may be below our detectable limit using LC/MS/MS analysis.
To test a spinal mechanism of action the observed FAAH inhibited anti-allodynic effects,
we treated mice with LPS followed 22hrs by PF-3845 intrathecally, then assessed paw
withdrawal thresholds. Mice treated with intrathecal PF-3845 showed a significant reversal of
paw withdrawal thresholds. Conversely, the dose of PF-3845 that reversed paw withdrawal
thresholds intrathecally also increased brain anandamide levels suggesting that drug spread in
fact occurred. Since intrathecal administration of low doses of PF-3845 resulted in increased
brain levels of anandamide, we could not determine with certainty if FAAH located spinally, or
supraspinally mediated the anti-allodynic effects seen in our previous studies with FAAH
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inhibition. To delineate spinal vs supraspinal FAAH contributions, future studies should conduct
dose response and time course studies for intrathecal and intracranial injections and choose a
dose/time point that does not increase systemic levels of endogenous cannabinoids. When we
find a dose or drug that can produce these effects will we be able to dissociate spinal from
supraspinal contributions.
The anti-allodynic effects of systemic and local FAAH inhibition were mediated via both
CB1 and CB2 receptors. Furthermore, we showed that FAAH (-/-) mice anti-allodynic effects
were also blocked with rimonabant and SR144528. These data are perplexing in that it is
believed that cannabinoids mediate their antinociceptive and antihyperalgesic responses via CB1
receptors whereas the anti-edematous effects are mediated through the CB2 receptors. However,
our data could not explain how each receptor was mediating FAAHs effects.
Our efforts to assess MAGL inhibition failed due to the fact that we could not complete
full characterization of these studies. JZL184 (40 mg/kg) administration resulted in
hyperreflexia when administered to mice, therefore presenting a false positive. This property
was recently noted in a paper from our laboratory while observing the effects of MAGL
inhibition in the tetrad studies (Long et al., 2009b). Full characterization such as dose-response
and time course studies should be conducted before further conclusions are made about the
effects of MAGL inhibition in the LPS-induced allodynia model.
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6.4 Final Discussion
The purpose of this dissertation was to evaluate targeting the endocannabinoid system to
reduce nociception. The results reported in this dissertation support the hypotheses that
phytocannabinoids as well as elevating endogenous cannabinoids block nociception in the acetic
acid abdominal stretching model and the LPS-induced allodynia model of inflammation. The
antinociceptive effects were mediate via CB1 receptors in both models of pain, and the CB2
receptor in the LPS model only. Although the mechanism of action for the CB2 receptor
mediated effects could not be fully elucidated in these studies there are a couple possibilities for
its involvement. Pain pathways are described at three different levels: in the periphery where it
originates, in the spinal cord where transmission is integrated, and in the CNS (particularly in the
PAG) where pain is processed (Figure 32). The first possibility stems from previous literature
where it was illustrated that the CB2 receptor is upregulated in the dorsal root ganglia and paw
tissue of rodents administered complete freund’s adjuvant (Hsieh et al., 2011). If this is case,
why do we only see a CB2 receptor mediated component in the inflammatory model and not the
visceral pain model? The answer to this question is complex, however one can argue that the
LPS model unlike the acetic acid model has a longer development cycle. Acetic acid abdominal
stretching is assessed within twenty minutes after acetic acid administration, whereas LPS
induced allodynia is assessed 24 h after LPS administration. Consequently, there is more time
for the CB2 receptor to be transcribed and transported to the nerve terminals. A similar effect of
CB2 receptor involvement is noted in a report from our laboratory demonstrating that the
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antinociceptive effects of FAAH inhibition are abolished in CB2 knockout mice in the chronic
constriction injury model (Kinsey et al., 2009) which also has a long development period.
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Figure 33. Schematic of FAAH loci of action. The figure illustrates the possible loci of action
of FAAH mediated effects. The effects can take place locally in the paw, spinally, or
supraspinally. Inhibiting FAAH in either region can increase anandamide levels and prolong the
activation of the cannabinoid receptors within these regions.
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Another possibility is that allodynia in the LPS induced model of inflammation may be driven by
the release of cytokines. It is known that there is an infiltration of macrophages in response to an
inflammatory agent such as LPS in our case, which results in the increase release of cytokines
local to the site of injection. It is also known that these infiltrating cells contain CB2 receptors,
and activation of the receptor can decrease the release of their inflammatory mediators.
Therefore, FAAH inhibition increases anandamide levels, which in turn bind to and activate the
CB2 receptor located on the infiltrating macrophages and ultimately decrease the release of
cytokines, resulting in a reversal of paw withdrawal thresholds. Although cytokines increase
nociceptor sensitivity (Sommer and Kress, 2004) we are not sure if they are still affecting
nociceptor functioning at the 24 hr time point after initial induction of inflammation. It is
possible that cytokines are no longer being released from the invading cells therefore activation
of CB2 receptors on macrophages may or may not affect nociceptor stimulation.
Our studies also illustrated that the FAAH inhibited anti-allodynic effects were
completely reversed by either CB1 or CB2 antagonism. These data imply that activation of
either receptor alone can drive the anti-allodynic effect. Conversely, since activation of both
receptors do not produce an additive effect, may suggest that there is an all of none response of
cannabinoid activation beyond a certain endocannabinoid threshold. Another explanation is that
the downstream signaling processes due to the activation of the CB1 or CB2 receptors converge
with each other to produce similar outcomes.
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The question still remain as to where in the neural axis FAAH inhibited anti-allodynic
effects are manifested, and how are both cannabinoid receptors mediate different effects in
different models. Taken together, the data presented in this dissertation suggest that
phytocannabinoids as well as FAAH and MAGL inhibition represents a promising target for the
treatment of various types of pain.
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